MBA, Business Administration, University of South Florida, 2000
MD, Medicine, Temple University, 1982
Interdisciplinary and Emerging Signature Programs
Neuroscience
Research Interests
Dr. Hauser has authored or co-authored more than 400 peer-reviewed publications and is one of the world's most cited Parkinson's Disease and Movement Disorders investigators. He is Past Chairman of the Interventional Neurology Section of the American Academy of Neurology, has served on the executive committee of the Parkinson Study Group, and was a member of the steering committee for the NIH-sponsored Neuroprotective Exploratory Trials in Parkinson's Disease program (NET-PD). Dr. Hauser lectures frequently at scientific meetings and served as Chairman of the 2009 World Federation of Neurology International Congress on Parkinson's Disease and Related Disorders. Dr. Hauser's primary research interest is the development of new medical and surgical treatments for Parkinson's disease and other movement disorders. He has extensive expertise in clinical trial design and execution. The outcome measures he developed have become the gold standard for use in clinical trials. He provides expert clinical care for patients with Parkinson's disease and botulinum toxin injections for cervical dystonia, blepharospasm, and hemifacial spasm.
Awards/Honors
America'a Top Doctors (Top 1%) (Castle Connolly - 2013)
Board Certification (American Society of Neuroimaging (MRI - Magnetic Resonance Imaging) - 2012)
Board Certification (American Board of Psychiatry & Neurology - 2012)
America'a Top Doctors (Top 1%) (Castle Connolly - 2012)
America's Top Doctors (Castle Connolly - 2011)
America's Top Doctors (Castle Connolly - 2010)
America's Top Doctors (Castle Connolly - 2009)
America's Top Doctors (Castle Connolly - 2008)
America's Top Doctors (Castle Connolly - 2008)
America's Top Doctors (Castle Connolly - 2007)
America's Top Doctors (Castle Connolly - 2006)
MIllion Dollar Researcher (University of South Florida - 2006)
America's Top Doctors (Castle Connolly - 2005)
Center of Excellence (National Parkinson Foundation - 2005)
America's Top Doctors (Castle Connolly - 2004)
America's Top Doctors (Castle Connolly - 2003)
Memberships
Fellow (American Academy of Neurology, 2004 - Present)
Member (Movement Disorders Society, 1988 - Present)
Member (American Academy of Neurology, 1988 - Present)
Recent Publications
Olanow, C. Warren|Hauser, Robert A.|Burdick, Daniel J.|Dhall, Rohit|de Marcaida, Joy Antonelle|Gil, Ramon A.|Kreitzman, David L.|Elmer, Lawrence W.|McGarry, Andrew|Kieburtz, Karl A Randomized Phase 3 Study Comparing P2B001 to its Components (Low‐Dose Extended‐Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended‐Release Pramipexole in Early Parkinson's DiseaseMovement Disorders [08853185]. 39(2) , 2024.
Fung, Victor S.C.|Aldred, Jason|Arroyo, Martha P.|Bergquist, Filip|Boon, Agnita J.W.|Bouchard, Manon|Bray, Sarah|Dhanani, Sara|Facheris, Maurizio F.|Fisseha, Nahome|Freire-Alvarez, Eric|Hauser, Robert A.|Jeong, Anna|Jia, Jia|Kukreja, Pavnit|Soileau, Michael J.|Spiegel, Amy M.|Talapala, Saritha|Tarakad, Arjun|Urrea-Mendoza, Enrique|Zamudio, Jorge|Pahwa, Rajesh Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson’s disease: Considerations for initiation and maintenanceClinical Parkinsonism & Related Disorders [25901125]. 10, 2024.
Fernandez, Hubert H.|Macklin, Eric A.|Hauser, Robert A.|Chou, Kelvin L.|Cakmak, Yusuf O.|Ozsoy, Burak|Fahn, Stanley Intrinsic auricular muscle zone stimulation for Parkinson disease: The EARSTIM-PD Phase II multi-center pilot study resultsParkinsonism and Related Disorders [13538020]. 121, 2024.
Hauser, Robert A.|Videnovic, Aleksandar|Soares-da-Silva, Patrício|Liang, Grace S.|Olson, Kurt|Jen, Eric|Rocha, José-Francisco|Klepitskaya, Olga OFF-times before, during, and after nighttime sleep periods in Parkinson's disease patients with motor fluctuations and the effects of opicapone: A post hoc analysis of diary data from BIPARK-1 and -2Parkinsonism and Related Disorders [13538020]. 123, 2024.
Espay, Alberto J.|Hauser, Robert A.|Dhall, Rohit|Thakkar, Sandeep|Cloud, Leslie|Zeitlin, Leonid|Banisadr, Ghazal|Fisher, Stanley|Visser, Hester Safety and Efficacy of IPX203 in Parkinson's Disease: The RISE‐PD Open‐Label Extension StudyMovement Disorders [08853185]. 39(2) , 2024.
Frank, Samuel|Anderson, Karen E.|Fernandez, Hubert H.|Hauser, Robert A.|Claassen, Daniel O.|Stamler, David|Factor, Stewart A.|Jimenez-Shahed, Joohi|Barkay, Hadas|Wilhelm, Amanda|Alexander, Jessica K.|Chaijale, Nayla|Barash, Steve|Savola, Juha-Matti|Gordon, Mark Forrest|Chen, Maria Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington DiseaseNeurology and Therapy [21938253]. , 2024.
Trosch, Richard M.|Comella, Cynthia L.|Caroff, Stanley N.|Ondo, William G.|Shillington, Alicia C.|LaChappelle, Brandon J.|Hauser, Robert A.|Correll, Christoph U.|Friedman, Joseph H. The Clinician’s Tardive Inventory (CTI): A New Clinical Tool for Documenting and Rating Tardive DyskinesiaThe Journal of Clinical Psychiatry [01606689]. 85(1) , 2024.
Hauser, R.A.|Factor, S.A.|Ondo, W.G.|Zhang, I.|Navia, B.|Pappert, E. Antiemetics may not be necessary for titration of apomorphine sublingual film for the treatment of "OFF" episodes in Parkinson's diseaseParkinsonism and Related Disorders [13538020]. 113, 2023.
Isaacson, Stuart H.|Hauser, Robert A.|Pahwa, Rajesh|Gray, David|Duvvuri, Sridhar Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatmentClinical Parkinsonism & Related Disorders [25901125]. 9, 2023.
Pappert, Eric|Zhang, Yi|Bowling, Alyssa|Navia, Bradford|Ondo, William G.|Hauser, Robert A.|Isaacson, Stuart H. Dose Optimization of Apomorphine Sublingual Film for OFF Episodes in Parkinson’s Disease: Is the Prophylactic Use of an Antiemetic Necessary?Journal of Parkinson's Disease [18777171]. 13(3) , 2023.
Comella, C.|Hauser, R.|Isaacson, S.|Truong, D.|Oguh, O.|Hui, J.|Molho, E.|Brodsky, M.|Furr-Stimming, E.|Comes, G.|Hast, M.|Charles, D. IncobotulinumtoxinA injections at intervals <10 weeks are effective and safe for cervical dystonia patients with inadequate benefit from standard intervalsParkinsonism and Related Disorders [13538020]. 113, 2023.
Comella, Cynthia|Hauser, Robert|Isaacson, Stuart|Truong, Daniel|Oguh, Odinachi|Hui, Jennifer|Molho, Eric|Brodsky, Matthew|Furr-Stimming, Erin|Comes, Georg|Hast, Michael|Charles, David Injections of incobotulinumtoxina at intervals less than 10 weeks are effective and safe for cervical dystonia patients with inadequate benefit from standard injection intervalsJournal of the Neurological Sciences [0022510X]. 455, 2023.
Hauser, Robert A.|Espay, Alberto J.|Ellenbogen, Aaron L.|Fernandez, Hubert H.|Isaacson, Stuart H.|LeWitt, Peter A.|Ondo, William G.|Pahwa, Rajesh|Schwarz, Johannes|Stocchi, Fabrizio|Zeitlin, Leonid|Banisadr, Ghazal|Fisher, Stanley|Visser, Hester|D’Souza, Richard IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease: The RISE-PD Randomized Clinical TrialArchives of Neurology [00039942]. 80(10) , 2023.
Vaswani, Pavan A.|Morley, James F.|Jennings, Danna|Siderowf, Andrew|Marek, Kenneth|Seibyl, John|Stern, Matthew|Russell, David|Sethi, Kapil|Frank, Samuel|Simuni, Tanya|Hauser, Robert|Ravina, Bernard|Richards, Irene|Liang, Grace|Adler, Charles|Saunders-Pullman, Rachel|Evatt, Marian L.|Lai, Eugene|Subramanian, Indu|Hogarth, Penelope|Chung, Kathryn Predictive value of abbreviated olfactory tests in prodromal Parkinson diseasenpj Parkinson's Disease [23738057]. 9(1) , 2023.
Trosch, Richard M.|Comella, Cynthia L.|Caroff, Stanley N.|Ondo, William G.|Shillington, Alicia C.|LaChappelle, Brandon J.|Hauser, Robert A.|Correll, Christof U.|Friedman, Joseph H. Reliability of the Clinician’s Tardive Inventory (CTI)CNS Spectrums [10928529]. 28(2) , 2023.
Martino, Davide|Karnik, Vikram|Bhidayasiri, Roongroj|Hall, Deborah A.|Hauser, Robert A.|Macerollo, Antonella|Pringsheim, Tamara M.|Truong, Daniel|Factor, Stewart A.|Skorvanek, Matej|Schrag, Anette Scales for Antipsychotic‐Associated Movement Disorders: Systematic Review, Critique, and RecommendationsMovement Disorders [08853185]. 38(6) , 2023.
Grosset, Donald G.|Blank, Burkhard|Waters, Cheryl H.|LeWitt, Peter A.|Hauser, Robert A. The Clinical Development of Levodopa Inhalation PowderClinical Neuropharmacology [03625664]. 46(2) , 2023.
Comella, C.|Isaacson, S.|Charles, D.|Truong, D.|Oguh, O.|Hui, J.|Molho, E.|Brodsky, M.|Furr-Stimming, E.|Comes, G.|Hast, M.|Hauser, R. Treatment of cervical dystonia using shorter incobotulinumtoxinA injection intervals improves patient-reported outcomes in those with inadequate benefits from standard intervalsParkinsonism and Related Disorders [13538020]. 113, 2023.
Isaacson, Stuart|Charles, David|Comella, Cynthia|Truong, Daniel|Oguh, Odinachi|Hui, Jennifer|Molho, Eric|Brodsky, Matthew|Furr-Stimming, Erin|Comes, Georg|Hast, Michael|Hauser, Robert Treatment of cervical dystonia using shorter incobotulinumtoxina injection intervals improves patient-reported outcomes in those with inadequate benefits from standard intervalsJournal of the Neurological Sciences [0022510X]. 455, 2023.
Morinan, Gareth|Hauser, Robert A.|Schrag, Anette|Tang, Jingxuan|O’Keeffe, Jonathan|MDS-NMS Scale Development Study Group Abbreviated MDS-UPDRS for Remote Monitoring in PD Identified Using Exhaustive Computational SearchParkinson's Disease [20908083]. 2022, 2022.
Hauser, Robert A.|Lytle, Judy|Formella, Andrea E.|Tanner, Caroline M. Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson’s diseasenpj Parkinson's Disease [23738057]. 8(1) , 2022.
Pahwa, Rajesh|Fox, Susan|Hauser, Robert A.|Isaacson, Stuart|Lytle, Judy|Johnson, Reed|Llorens, Lily|Formella, Andrea E.|Tanner, Caroline M. Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesiaFrontiers in Neurology [16642295]. 13, 2022.
Hauser, Robert A.|Meyer, Jonathan M.|Factor, Stewart A.|Comella, Cynthia L.|Tanner, Caroline M.|Xavier, Rose Mary|Caroff, Stanley N.|Lundt, Leslie Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practiceCNS Spectrums [10928529]. 27(2) , 2022.
Hauser, Robert A.|Favit, Antonella|Hewitt, L. Arthur|Lindsten, Annika|Gorny, Stephen|Kymes, Steven|Isaacson, Stuart H. Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label TreatmentNeurology and Therapy [21938253]. 11(1) , 2022.
Hauser, Robert A.|Barkay, Hadas|Fernandez, Hubert H.|Factor, Stewart A.|Jimenez-Shahed, Joohi|Gross, Nicholas|Marinelli, Leslie|Wilhelm, Amanda|Gordon, Mark Forrest|Savola, Juha-Matti|Anderson, Karen E. Effects of Long-Term Deutetrabenazine Treatment in Patients with Tardive Dyskinesia and Underlying Psychiatric or Mood DisordersCNS Spectrums [10928529]. 27(2) , 2022.
Comella, Cynthia|Hauser, Robert A.|Isaacson, Stuart H.|Truong, Daniel|Oguh, Odinachi|Hui, Jennifer|Molho, Eric S.|Brodsky, Matthew|Furr-Stimming, Erin|Comes, Georg|Hast, Michael A.|Charles, David Efficacy and safety of two incobotulinumtoxinA injection intervals in cervical dystonia patients with inadequate benefit from standard injection intervals of botulinum toxin: Phase 4, open-label, randomized, noninferiority studyClinical Parkinsonism & Related Disorders [25901125]. 6, 2022.
Hauser, Robert A.|Barkay, Hadas|Fernandez, Hubert H.|Factor, Stewart A.|Jimenez-Shahed, Joohi|Gross, Nicholas|Marinelli, Leslie|Wilhelm, Amanda|Alexander, Jessica|Gordon, Mark Forrest|Savola, Juha-Matti|Anderson, Karen E. Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension StudyFrontiers in Neurology [16642295]. 13, 2022.
Hauser, Robert A.|Barkay, Hadas|Fernandez, Hubert H.|Factor, Stewart A.|Jimenez-Shahed, Joohi|Gross, Nicholas|Marinelli, Leslie|Wilhelm, Amanda|Gordon, Mark Forrest|Savola, Juha-Matti|Anderson, Karen E. Long-Term Efficacy and Safety of Deutetrabenazine in Patients with Tardive Dyskinesia by Concomitant Dopamine-Receptor Antagonist UseCNS Spectrums [10928529]. 27(2) , 2022.
Hauser, Robert A.|Barkay, Hadas|Wilhelm, Amanda|Wieman, Maria|Savola, Juha-Matti|Gordon, Mark Forrest Minimal clinically important change in Abnormal Involuntary Movement Scale score in tardive dyskinesia as assessed in pivotal trials of deutetrabenazineParkinsonism and Related Disorders [13538020]. 97, 2022.
Camilleri, Michael|Subramanian, Thyagarajan|Pagan, Fernando|Isaacson, Stuart|Gil, Ramon|Hauser, Robert A.|Feldman, Mary|Goldstein, Mark|Kumar, Rajeev|Truong, Daniel|Chhabria, Nisha|Walter, Benjamin L.|Eskenazi, Jonathan|Riesenberg, Robert|Burdick, Daniel|Tse, Winona|Molho, Eric|Robottom, Bradley|Bhatia, Perminder|Kadimi, Srinath|Klos, Kevin|Shprecher, David|Marquez-Mendoza, Otto|Hidalgo, Gonzalo|Grill, Stephen|Li, George|Mandell, Howard|Hughes, Mary|Stephenson, Sharisse|Vandersluis, Joel|Pfeffer, Michael|Duker, Andrew|Shivkumar, Vikram|Kinney, William|MacDougall, James|Zasloff, Michael|Barbut, Denise Oral ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease: A Randomized Controlled TrialAnnals of Internal Medicine [00034819]. 175(12) , 2022.
Hauser, Robert A.|Giladi, Nir|Poewe, Werner|Brotchie, Jonathan|Friedman, Hadas|Oren, Sheila|Litman, Pninit P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson’s DiseaseAdvances in Therapy [0741238X]. 39(5) , 2022.
Hauser, Robert A.|Goud, Santosh|Formella, Andrea E. Potential Utility of Amantadine DR/ER in Persons with Parkinson’s Disease Meeting 5-2-1 Criteria for Device Aided TherapyClinical Parkinsonism & Related Disorders [25901125]. 6, 2022.
Soileau, Michael J|Aldred, Jason|Budur, Kumar|Fisseha, Nahome|Fung, Victor SC|Jeong, Anna|Kimber, Thomas E|Klos, Kevin|Litvan, Irene|O'Neill, Daniel|Robieson, Weining Z|Spindler, Meredith A|Standaert, David G|Talapala, Saritha|Vaou, Eleni Okeanis|Zheng, Hui|Facheris, Maurizio F|Hauser, Robert A Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trialLancet Neurology [14744422]. 21(12) , 2022.
Dukart, Juergen|D’Urso, Giulia|Finch, Rebecca|Zanigni, Stefano|Monnet, Annabelle|Pross, Nathalie|Hahn, Andrea|Svoboda, Hanno|Britschgi, Markus|Lipsmeier, Florian|Volkova-Volkmar, Ekaterina|Lindemann, Michael|Dziadek, Sebastian|Holiga, Štefan|Rukina, Daria|Kustermann, Thomas|Kerchner, Geoffrey A.|Fontoura, Paulo|Umbricht, Daniel|Doody, Rachelle|Nikolcheva, Tania|Bonni, Azad|Pagano, Gennaro|Taylor, Kirsten I.|Anzures-Cabrera, Judith|Marchesi, Maddalena|Simuni, Tanya|Marek, Kenneth|Postuma, Ronald B.|Pavese, Nicola|Stocchi, Fabrizio|Azulay, Jean-Philippe|Mollenhauer, Brit|López-Manzanares, Lydia|Russell, David S.|Boyd, James T.|Nicholas, Anthony P.|Luquin, María R.|Hauser, Robert A.|Gasser, Thomas|Poewe, Werner|Ricci, Benedicte|Boulay, Anne|Vogt, Annamarie|Boess, Frank G. Trial of Prasinezumab in Early-Stage Parkinson’s DiseaseNew England Journal of Medicine [00284793]. 387(5) , 2022.
Rupprechter, Samuel|Morinan, Gareth|Peng, Yuwei|Foltynie, Thomas|Sibley, Krista|Weil, Rimona S.|Leyland, Louise-Ann|Baig, Fahd|Morgante, Francesca|Gilron, Ro’ee|Wilt, Robert|Starr, Philip|Hauser, Robert A.|O’Keeffe, Jonathan A Clinically Interpretable Computer-Vision Based Method for Quantifying Gait in Parkinson’s DiseaseSensors [14248220]. 21(16) , 2021.
Jankovic, Joseph|Comella, Cynthia|Hauser, Robert A.|Patel, Atul T.|Gross, Todd M.|Rubio, Roman G.|Vitarella, Domenico A phase 3 trial evaluating the efficacy, duration of effect, and safety of daxibotulinumtoxinA for injection in the treatment of cervical dystoniaToxicon [00410101]. 190, 2021.
Lew, Mark F.|Hauser, Robert A.|Isaacson, Stuart H.|Truong, Daniel|Patel, Atul T.|Brashear, Allison|Ondo, William|Maisonobe, Pascal|Dashtipour, Khashayar|Bahroo, Laxman|Wietek, Stefan AbobotulinumtoxinA provides flexibility for the treatment of cervical dystonia with 500 U/1 mL and 500 U/2 mL dilutionsClinical Parkinsonism & Related Disorders [25901125]. 5, 2021.
Esquenazi, Alberto|Delgado, Mauricio R.|Hauser, Robert A.|Lysandropoulos, Andreas|Gracies, Jean-Michel AbobotulinumtoxinA: Evidence for long duration of response from 5 patient populationsToxicon [00410101]. 190, 2021.
Hauser, Robert A.|Walsh, Ryan R.|Pahwa, Rajesh|Chernick, Dustin|Formella, Andrea E. Amantadine ER (Gocovri®) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's DiseaseFrontiers in Neurology [16642295]. 12, 2021.
Patel, Atul T.|Lew, Mark F.|Dashtipour, Khashayar|Isaacson, Stuart|Hauser, Robert A.|Ondo, William|Maisonobe, Pascal|Wietek, Stefan|Rubin, Bruce|Brashear, Allison Correction: Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b studyPLoS ONE [19326203]. 16(4) , 2021.
Pringsheim, Tamara|Day, Gregory S.|Smith, DonB.|Rae-Grant, Alex|Licking, Nicole|Armstrong, Melissa J.|de Bie, Rob M. A.|Roze, Emmanuel|Miyasaki, Janis M.|A.Hauser, Robert|Espay, Alberto J.|Martello, Justin P.|Gurwell, Julie|Billinghurst, Lori|Sullivan, Kelly|Fitts, Michael S.|Cothros, Nicholas|Hall, Deborah A.|Rafferty, Miriam|Hagerbrant, Lynn|Hastings, Tara|O’Brien, Mary Dolan|Silsbee, Heather|Gronseth, Gary|Lang, Anthony E.|Lang, Anthony E.|Pringsheim, Tamara|Day, Gregory S.|Smith, Don B.|Rae-Grant, Alex|Licking, Nicole|Armstrong, Melissa J.|de Bie, Rob M.A.|Roze, Emmanuel|Miyasaki, Janis M.|Hauser, Robert A.|Espay, Alberto J.|Martello, Justin P.|Gurwell, Julie A.|Billinghurst, Lori|Sullivan, Kelly|Fitts, Michael S.|Cothros, Nicholas|Hall, Deborah A.|Rafferty, Miriam|Hagerbrant, Lynn|Hastings, Tara|O'Brien, Mary Dolan|Silsbee, Heather|Gronseth, Gary Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline SubcommitteeNeurology [00283878]. 97(20) , 2021.
Hauser, Robert A.|Zeitlin, Leonid|Fisher, Stanley|D'Souza, Richard Duration of benefit per Dose: Carbidopa-Levodopa immediate release vs. extended release capsules (Rytary®)Parkinsonism and Related Disorders [13538020]. 82, 2021.
Jimenez-Shahed, Joohi|Barkay, Hadas|Anderson, Karen E.|Fernandez, Hubert H.|Factor, Stewart A.|Hauser, Robert A.|Wieman, Maria|Gordon, Mark Forrest|Savola, Juha-Matti Effect of Deutetrabenazine on Metabolic Parameters in the Treatment of Tardive DyskinesiaCNS Spectrums [10928529]. 26(2) , 2021.
Ahmed, Anwar|Mari, Zoltan|Waters, Cheryl|Ratel, Amber Servi|Saint-Hilaire, Marie|Waikar, Sushrut S.|Curhan, Gary C.|McMahon, Gearoid Michael|Friedman, Joseph Harold|James, Raymond|McGraw, Martha|Zhang, Lin|Bluett, Brent|Togasaki, Daniel M.|Mihaila, Dragos|Evatt, Marian|Rezak, Michael|Jain, Samay|Stover, Natividad|Soileau, Michael|Goetz, Christopher|Kumar, Rajeev|LaFaver, Kathrin|Simuni, Tanya|Poon, Cynthia|Laroche, Ashley|Thomas, Karen|Fitzgerald, Rebecca|Houghton, David J.|Macklin, Eric A.|Goudreau, John|Russell, Doozie|Hinson, Vanessa|Blindauer, Karen|Schwarzschild, Michael A.|Callahan, Katherine F.|Crotty, Grace F.|Klements, David|Pothier, Lindsay|Hung, Albert|Bwala, Grace|Videnovic, Aleksandar|Rosenthal, Liana|Beck, Christopher A.|Deik, Andres F.|Shah, Binit B.|Serrano, Carmen|Criswell, Susan R.|Schiess, Mya C.|Fang, John Y.|Cloud, Leslie|Espay, Alberto J.|Leehey, Maureen|Chou, Kelvin|Pahwa, Rajesh|Langhammer, April|Christine, Chadwick|Daley, Aaron|Litvan, Irene|Dewey, Richard B.|Gerald, Ashley|LeDoux, Mark S.|Bhatti, Danish|Peterson, Carolyn|Reich, Stephen|Park, Ariane|Casaceli, Cindy|Kamp, Cornelia|Oakes, David|Rudolph, Alice|Schneider, Ruth B.|Bolger, Patrick|Kostrzebski, Melissa|Mozaffarian, Dariush|Mestre, Tiago|Suski, Valerie|Mosovsky, Sherri|Hauser, Robert A.|Lang, Anthony|Houston, Emily|Shoulson, Ira|Ascherio, Alberto|Marek, Kenneth|Bixby, Melissa|Ciccarello, Jill|Zauber, Sarah Elizabeth|LeWitt, Peter A.|Kaminski, Patricia|Gauger, Lisa|Scott, Burton|Durphy, Jennifer|Simon, David K.|de Marcaida, J. Antonelle|Bodis-Wollner, Ivan|Henchcliffe, Claire|Gunzler, Steven A.|Boyd, James T.|Mehta, Shyamal H.|Brodsky, Matthew|Keith, Kellie|Jimenez-Shahed, Joohi|Aldred, Jason|Lungu, Codrin|Rabin, Marcie|Kurlan, Roger|Ainslie, Melissa|Hunter, Christine|Morgan, John C.|Shill, Holly A.|Shprecher, David Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical TrialJournal of the American Medical Association [00987484]. 326(10) , 2021.
Mehta, Shyamal H.|Pahwa, Rajesh|Tanner, Caroline M.|Hauser, Robert A.|Johnson, Reed Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson’s Disease and DyskinesiaNeurology and Therapy [21938253]. 10(1) , 2021.
Hauser, Robert A.|Mehta, Shyamal H.|Kremens, Daniel|Chernick, Dustin|Formella, Andrea E. Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People with Parkinson’s Disease and DyskinesiaNeurology and Therapy [21938253]. 10(2) , 2021.
Hauser, Robert A.|Hattori, Nobutaka|Fernandez, Hubert|Isaacson, Stuart H.|Mochizuki, Hideki|Rascol, Olivier|Stocchi, Fabrizio|Li, June|Mori, Akihisa|Nakajima, Yu|Ristuccia, Robert|LeWitt, Peter Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson’s Disease: A Pooled Analysis of 8 Phase 2b/3 TrialsJournal of Parkinson's Disease [18777171]. 11(4) , 2021.
Venuto, Charles|Baker, Liana|Kostrzebski, Melissa|Matthews, Helen|Wyse, Richard K.|Fiske, Brian|Brundin, Patrik|Ward, Tina|Simuni, Tanya|Dawson, Ted M.|Merchant, Kalpana|Schwarzschild, Michael|Coffey, Christopher S.|Klingner, Elizabeth|Caspell-Garcia, Chelsea|Lafontant, David-Erick|Adams, Jamie|Augustine, Erika|Baker, Deborah|Brocht, Alicia|Casaceli, Cindy|Eaton, Ken|Henderson, Sue|McMullen, Nichole|Muneath, Phounsavath|Trusso, Laura|Field, Carlinda|Brahmachari, Saurav|Rosenthal, Liana|Carman, Emily|Kamp, Cornelia|Bolger, Patrick|Wegel, Claire|Reynolds, Holly|Levy, Oren|Servi, Amber|Chou, Kelvin|Stovall, Angela S|Pal, Gian|Keith, Kellie|Chung, Kathryn|Shahed, Joohi|Hunter, Christine|Shah, Binit|Sullivan, Katie|Hung, Albert Y.|Bwala, Grace|Spindler, Meredith|Oliver, Alexandria|Hauser, Robert A.|Rocha, Claudia|Molho, Eric|Evans, Sharon|Shill, Holly A.|Ismail, Farah|Stover, Natividad|Cromer, Candace|Blair, Courtney|Zhang, Lin|Kishchenko, Olga|Swan, Matthew|Ramirez, Laura|Frank, Samuel|Burrows, Stephanie|Duker, Andrew|Gruenwald, Christina|Blindauer, Karen|Wheeler, Lynn|Seeberger, Lauren|Simpson, Abigail|Scott, Burton L.|Gauger, Lisa|Ahmed, Anwar|Pitchford, Yvette|Mule, Jennifer|Ramirez-Zamora, Adolfo|Ridgeway, Derek B.|Slevin, John Slevin|Wagner, Renee Wagner|Hinson, Vanessa|Jenkins, Shonna|Goudreau, John L.|Russell, Doozie|Mari, Zoltan|Dumitrescu, Lilliana|Aldred, Jason|Bixby, Melissa|LeDoux, Mark|Rafaloff, Gary|Adams, Jamie|Weiner, David|Simon, David K. Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical TrialArchives of Neurology [00039942]. 78(3) , 2021.
Naito, Anna|Wills, Anne-Marie|Tropea, Thomas F.|Ramirez-Zamora, Adolfo|Hauser, Robert A.|Martino, Davide|Turner, Travis H.|Rafferty, Miriam R.|Afshari, Mitra|Williams, Karen L.|Vaou, Okeanis|McKeown, Martin J.|Ginsburg, Letty|Ezra, Adi|Iansek, Robert|Wallock, Kristin|Evers, Christiana|Schroeder, Karlin|DeLeon, Rebeca|Yarab, Nicole|Alcalay, Roy N.|Beck, James C. Expediting telehealth use in clinical research studies: recommendations for overcoming barriers in North Americanpj Parkinson's Disease [23738057]. 7(1) , 2021.
Jenner, Peter|Mori, Akihisa|Aradi, Stephen D.|Hauser, Robert A. Istradefylline – a first generation adenosine A 2A antagonist for the treatment of Parkinson’s diseaseExpert Review of Neurotherapeutics [14737175]. 21(3) , 2021.
Hauser, Robert A.|Barkay, Hadas|Fernandez, Hubert H.|Factor, Stewart A.|Jimenez-Shahed, Joohi|Gross, Nicholas|Marinelli, Leslie|Wilhelm, Amanda|Gordon, Mark Forrest|Savola, Juha-Matti|Anderson, Karen E. Long-Term Deutetrabenazine Treatment Is Associated With Continued Improvement in Tardive Dyskinesia in the Completed 3-Year Open-Label Extension StudyCNS Spectrums [10928529]. 26(2) , 2021.
Barkay, Hadas|Hauser, Robert A.|Wilhelm, Amanda|Wieman, Maria|Gordon, Mark Forrest|Savola, Juha-Matti Minimal Clinically Important Difference in AIMS Score Based on CGIC and PGIC in Patients With Tardive Dyskinesia Treated With DeutetrabenazineCNS Spectrums [10928529]. 26(2) , 2021.
LeWitt, Peter A.|Comella, Cynthia L.|Hauser, Robert A. On demand therapy for Parkinson’s disease patients: Opportunities and choicesPostgraduate Medicine [00325481]. 133(7) , 2021.
Roberts, Angela C.|Rafferty, Miriam R.|Wu, Samuel S.|Miao, Guanhuong|Cubillos, Fernando|Simuni, Tanya|Marras, Connie|Davis, Tom|Dahodwala, Nabila|Neault, Marilyn|Ramirez-Zamora, Adolfo|Rafferty, Miriam|Malaty, Irene|Parashos, Sotirios|Kraakevik, Jeff|Simuni, Tanya|Dahodwala, Nabila|Jankovic, Joseph|Simon, David|Pahwa, Rajesh|Mills, Kelly|Way, Christopher|Morgan, John|Pagan, Fernando|Hauser, Robert|Davis, Thomas|Salins, Naomi|Gurevich, Tanya|Bloem, Bastiaan|Marras, Connie|Singer, Carlos|Lafontaine, Anne Louise|Feigin, Andrew|Miyasaki, Janis|Litvan, Irene Patterns and predictors of referrals to allied health services for individuals with Parkinson's disease: A Parkinson's foundation (PF) QII studyParkinsonism and Related Disorders [13538020]. 83, 2021.
Dashtipour, Khashayar|Gupta, Fiona|Hauser, Robert A.|Karunapuzha, Cherian A.|Morgan, John C. Pimavanserin Treatment for Parkinson’s Disease Psychosis in Clinical PracticeParkinson's Disease [20908083]. 2021, 2021.
Hauser, Robert A.|Banisadr, Ghazal|Vuong, Kara|Freilich, David|Fisher, Stanley|D’Souza, Richard Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary®): Results of a Nationwide Dose Conversion SurveyParkinson's Disease [20908083]. 2021, 2021.
Videnovic, Aleksandar|Amara, Amy W.|Comella, Cynthia|Schweitzer, Paula K.|Emsellem, Helene|Liu, Kris|Sterkel, Amanda L.|Gottwald, Mildred D.|Steinerman, Joshua R.|Jochelson, Philip|Zomorodi, Katie|Hauser, Robert A. Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof‐of‐Concept TrialMovement Disorders [08853185]. 36(10) , 2021.
Patel, Atul T.|Lew, Mark F.|Dashtipour, Khashayar|Isaacson, Stuart|Hauser, Robert A.|Ondo, William|Maisonobe, Pascal|Wietek, Stefan|Rubin, Bruce|Brashear, Allison Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b studyPLoS ONE [19326203]. 16(2) , 2021.
Hauser, Robert A.|Barkay, Hadas|Fernandez, Hubert H.|Factor, Stewart A.|Jimenez-Shahed, Joohi|Gross, Nicholas|Marinelli, Leslie|Forrest Gordon, Mark|Savola, Juha-Matti|Anderson, Karen E. 134 Long-Term Deutetrabenazine Treatment Is Associated with Sustained Treatment Response in Tardive Dyskinesia: Results from an Open-Label Extension StudyCNS Spectrums [10928529]. 25(2) , 2020.
Fernandez, Hubert H.|Barkay, Hadas|Hauser, Robert A.|Factor, Stewart A.|Jimenez-Shahed, Joohi|Gross, Nicholas|Marinelli, Leslie|Gordon, Mark Forrest|Savola, Juha-Matti|Anderson, Karen E. 151 Confirmed Safety of Deutet.rabenazine for Tardive Dyskinesia in a 3-Year Open-Label Extension StudyCNS Spectrums [10928529]. 25(2) , 2020.
Farbman, Eric S.|Waters, Cheryl H.|LeWitt, Peter A.|Rudzińska, Monika|Klingler, Michael|Lee, Angela|Qian, Jenny|Oh, Charles|Hauser, Robert A. A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's diseaseParkinsonism and Related Disorders [13538020]. 81, 2020.
Olanow, C Warren|Factor, Stewart A|Espay, Alberto J|Hauser, Robert A|Shill, Holly A|Isaacson, Stuart|Pahwa, Rajesh|Leinonen, Mika|Bhargava, Parul|Sciarappa, Ken|Navia, Bradford|Blum, David|xx, xx Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 studyLancet Neurology [14744422]. 19(2) , 2020.
Hauser, Robert A.|Zeitlin, Leonid|Fisher, Stanley|D’Souza, Richard Carbidopa and Levodopa Extended Release Capsules in Patients with and without Troublesome and Non-Troublesome DyskinesiaJournal of Parkinson's Disease [18777171]. 10(3) , 2020.
Eberly, Shirley|Oakes, David|Siderowf, Andrew|Stern, Matthew|Jennings, Danna|Seibyl, John|Marek, Kenneth Clinical and Imaging Progression in the PARS Cohort: Long‐Term Follow‐upMovement Disorders [08853185]. 35(9) , 2020.
Mills, Kelly A.|Schneider, Ruth B.|Saint-Hilaire, Marie|Ross, G. Webster|Hauser, Robert A.|Lang, Anthony E.|Halverson, Matthew J.|Oakes, David|Eberly, Shirley|Litvan, Irene|Blindauer, Karen|Aquino, Camila|Simuni, Tanya|Marras, Connie Cognitive impairment in Parkinson's disease: Associations between subjective and objective cognitive decline in a large longitudinal studyParkinsonism and Related Disorders [13538020]. 80, 2020.
Esquenazi, Alberto|Delgado, Mauricio R.|Hauser, Robert A.|Picaut, Philippe|Foster, Keith|Lysandropoulos, Andreas|Gracies, Jean-Michel Duration of Symptom Relief Between Injections for AbobotulinumtoxinA (Dysport®) in Spastic Paresis and Cervical Dystonia: Comparison of Evidence From Clinical StudiesFrontiers in Neurology [16642295]. 11, 2020.
Hauser, Robert A.|Eidelberg, David|Riggare, Sara|Pahwa, Rajesh|Cenci, M. Angela Dyskinesia mattersMovement Disorders [08853185]. 35(3) , 2020.
Tanner, Caroline M.|Pahwa, Rajesh|Hauser, Robert A.|Oertel, Wolfgang H.|Isaacson, Stuart H.|Jankovic, Joseph|Johnson, Reed|Chernick, Dustin|Hubble, Jean EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson’s DiseaseJournal of Parkinson's Disease [18777171]. 10(2) , 2020.
Lew, M.F.|Hauser, R.A.|Isaacson, S.|Ferreira, J.J.|Serbin, M.|Farahmand, K.|Olson, K.|Klepitskaya, O.|Rocha, F.|Soares-da-Silva, P.|Liang, G.S. Efficacy of opicapone in Parkinson's patients with motor fluctuations and ON Hoehn & Yahr ≤2.5: post hoc analysis of BIPARK-1Parkinsonism and Related Disorders [13538020]. 79, 2020.
Bhidayasiri, Roongroj|Kane, John M.|Frei, Karen P.|Caroff, Stanley N.|Correll, Christoph U.|Fahn, Stanley|Jankovic, Joseph|Hauser, Robert A.|Truong, Daniel D. Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment toolParkinsonism and Related Disorders [13538020]. 77, 2020.
Simuni, Tanya|Merchant, Kalpana|Gan‐Or, Ziv|Levy, Oren|Alcalay, Roy N.|Chahine, Lana M.|Scherzer, Clemens|Foroud, Tatiana|Nudelman, Kelly|Blauwendraat, Cornelis|Chiang, Ming Sum Ruby|Sardi, Sergio Pablo|Hutten, Samantha J.|Wolf, Pavlina|Helesicova, Karolina|Zhang, Xiaokui Kate|Caspell‐Garcia, Chelsea|Zheng, Dandi|Li, Gen Longitudinal Measurements of Glucocerebrosidase activity in Parkinson’s patientsAnnals of Clinical and Translational Neurology [23289503]. 7(10) , 2020.
Aradi, Stephen D.|Hauser, Robert A. Medical Management and Prevention of Motor Complications in Parkinson's DiseaseNeurotherapeutics [19337213]. 17(4) , 2020.
Hauser, R.A.|Lew, M.F.|Comella, C.L.|Poewe, W.|Rascol, O.|Ferreira, J.J.|Olson, K.|Farahmand, K.|Shah, C.|Rocha, J.-F.|Soares-da-Silva, P.|Klepitskaya, O. Nighttime and morning OFF improvements with opicapone in patients with Parkinson's Disease and motor fluctuations: BIPARK-1 and BIPARK-2 pooled subanalysesParkinsonism and Related Disorders [13538020]. 79, 2020.
LeWitt, Peter A|Kymes, Steve|Hauser, Robert A Parkinson Disease and Orthostatic Hypotension in the Elderly: Recognition and Management of Risk Factors for FallsAging and Disease [21525250]. 11(3) , 2020.
Hauser, R.|Mehta, S.|Maulis, M.|Bhargava, P.|Navia, B.|Blum, D.|Pappert, E. Patient-reported motor responses to apomorphine sublingual film based on home dosing and response diariesParkinsonism and Related Disorders [13538020]. 79, 2020.
Wohlgemuth, William K.|Factor, Stewart A.|Wittine, Lara|Amara, Amy W.|Wallace, Douglas M.|Malaty, Irene A.|Trotti, Lynn Marie|Hauser, Robert A.|Nallu, Sagarika Practical Evaluation and Management of Insomnia in Parkinson's Disease: A ReviewMovement Disorders Clinical Practice [23301619]. 7(3) , 2020.
Hauser, Robert A.|Eidelberg, David|Pahwa, Rajesh|Riggare, Sara|Cenci, M. Angela Reply to: Letter to Editor by Chaudhuri, Jenner, AntoniniMovement Disorders [08853185]. 35(5) , 2020.
LeWitt, Peter A.|Aradi, Stephen D.|Hauser, Robert A.|Rascol, Olivier The challenge of developing adenosine A2A antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenantParkinsonism and Related Disorders [13538020]. 80, 2020.
Espay, Alberto J.|Hauser, Robert A.|Armstrong, Melissa J. The Narrowing Path for Nilotinib and Other Potential Disease-Modifying Therapies for Parkinson DiseaseArchives of Neurology [00039942]. 77(3) , 2020.
Hauser, R.A.|Klingler, M.|Abeynayake, I.|Roberts, H. UPDRS motor-score improvement after CVT-301 treatment is associated with improved scores in Parkinson's Disease Questionnaire (PDQ-39) activities of daily livingParkinsonism and Related Disorders [13538020]. 79, 2020.
Anderson, Karen E.|Stamler, David|Davis, Mat D.|Hauser, Robert A.|Jarskog, L. Fredrik|Jimenez-Shahed, Joohi|Kumar, Rajeev|Ochudlo, Stanislaw|McEvoy, Joseph|Fernandez, Hubert H. 34 Long-Term Deutetrabenazine Treatment Response in Tardive Dyskinesia by Concomitant Dopamine-Receptor Antagonists and Baseline ComorbiditiesCNS Spectrums [10928529]. 24(1) , 2019.
Anderson, Karen E.|Stamler, David|Davis, Mat D.|Gross, Nicholas|Hauser, Robert A.|Jarskog, L. Fredrik|Jimenez-Shahed, Joohi|Kumar, Rajeev|Ochudlo, Stanislaw|McEvoy, Joseph|Fernandez, Hubert H. 35 Long-term Improvements in Site-Rated Outcomes with Deutetrabenazine Treatment in Patients with Tardive DyskinesiaCNS Spectrums [10928529]. 24(1) , 2019.
Hauser, Robert A.|Fernandez, Hubert H.|Stamler, David|Davis, Mat D.|Factor, Stewart A.|Jimenez-Shahed, Joohi|Ondo, William G.|Jarskog, L. Fredrik|Woods, Scott W.|LeDoux, Mark S.|Shprecher, David R.|Anderson, Karen E. 45 Long-term Treatment with Deutetrabenazine Is Associated with Continued Improvement in Tardive Dyskinesia: Results from an Open-label Extension StudyCNS Spectrums [10928529]. 24(1) , 2019.
Fernandez, Hubert H.|Stamler, David|Davis, Mat D.|Factor, Stewart A.|Hauser, Robert A.|Jimenez-Shahed, Joohi|Ondo, William G.|Jarskog, L. Fredrik|Woods, Scott W.|LeDoux, Mark S.|Shprecher, David R.|Anderson, Karen E. 46 Confirmed Safety of Deutetrabenazine for Tardive Dyskinesia in a 2-Year Open-label Extension StudyCNS Spectrums [10928529]. 24(1) , 2019.
Ridgway, Sam H.|Brownson, Robert H.|Van Alstyne, Kaitlin R.|Hauser, Robert A. Higher neuron densities in the cerebral cortex and larger cerebellums may limit dive times of delphinids compared to deep-diving toothed whalesPLoS ONE [19326203]. 14(12) , 2019.
Hermanowicz, Neal|Jones, Sarah A|Hauser, Robert A Impact of non-motor symptoms in Parkinson’s disease: a PMDAlliance surveyNeuropsychiatric Disease and Treatment [11766328]. Volume 15, 2019.
Fernandez, Hubert H.|Stamler, David|Davis, Mat D.|Factor, Stewart A.|Hauser, Robert A.|Jimenez-Shahed, Joohi|Ondo, William G.|Jarskog, L. Fredrik|Woods, Scott W.|Bega, Danny|LeDoux, Mark S.|Shprecher, David R.|Anderson, Karen E. Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesiaJournal of Neurology, Neurosurgery and Psychiatry [00223050]. , 2019.
Hauser, R.|Rascol, O.|Poewe, W.|Ferreira, J.|Lees, A.|Klepitskaya, O.|Liang, G.|Santos, A.|Magalhaes, D.|Rocha, F.|Soares-da-Silva, P. Opicapone as a levodopa sparing agent: Pooled analysis of BIPARK-I and II double-blind trialsJournal of the Neurological Sciences [0022510X]. 405, 2019.
Hauser, Robert A.|Isaacson, Stuart H.|Ellenbogen, Aaron|Safirstein, Beth E.|Truong, Daniel D.|Komjathy, Steven F.|Kegler-Ebo, Deena M.|Zhao, Ping|Oh, Charles Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's diseaseParkinsonism and Related Disorders [13538020]. 64, 2019.
Hauser, Robert A.|Pahwa, Rajesh|Wargin, William A.|Souza-Prien, Cindy J.|McClure, Natalie|Johnson, Reed|Nguyen, Jack T.|Patni, Rajiv|Went, Gregory T. Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of DyskinesiaClinical Pharmacokinetics [03125963]. 58(1) , 2019.
Hauser, Robert A.|Kremens, Daniel E.|Elmer, Lawrence W.|Kreitzman, David L.|Walsh, Ryan R.|Johnson, Reed|Howard, Robert|Nguyen, Jack T.|Patni, Rajiv Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal TrialsJournal of Parkinson's Disease [18777171]. 9(3) , 2019.
LeWitt, Peter A|Hauser, Robert A|Pahwa, Rajesh|Isaacson, Stuart H|Fernandez, Hubert H|Lew, Mark|Saint-Hilaire, Marie|Pourcher, Emmanuelle|Lopez-Manzanares, Lydia|Waters, Cheryl|Rudzínska, Monika|Sedkov, Alexander|Batycky, Richard|Oh, Charles Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trialLancet Neurology [14744422]. 18(2) , 2019.
Hauser, Robert A.|Sutherland, Dean|Madrid, Juan A.|Rol, Maria Angeles|Frucht, Steven|Isaacson, Stuart|Pagan, Fernando|Maddux, Brian N.|Li, George|Tse, Winona|Walter, Benjamin L.|Kumar, Rajeev|Kremens, Daniel|Lew, Mark F.|Ellenbogen, Aaron|Oguh, Odinachi|Vasquez, Alberto|Kinney, William|Lowery, Matt|Resnick, Maria|Huff, Nicole|Posner, Jerry|Ballman, Karla V.|Harvey, Brian E.|Camilleri, Michael|Zasloff, Michael|Barbut, Denise Targeting neurons in the gastrointestinal tract to treat Parkinson's diseaseClinical Parkinsonism & Related Disorders [25901125]. 1, 2019.
Vollstedt, Eva‐Juliane|Klein, Christine|Kasten, Meike Using global team science to identify genetic Parkinson's disease worldwideAnnals of Neurology [03645134]. 86(2) , 2019.
Lew MF, Brashear A, Dashtipour K, Isaacson S, Hauser RA, Maisonobe P, Snyder D, Ondo W. A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystonia.Int J Neurosci 2018;128:619-626.. , 2018.
Fernandez, Hubert H.|Davis, Mat D.|Factor, Stewart A.|Hauser, Robert A.|Jarskog, L. Fredrik|Jimenez-Shahed, Joohi|Kumar, Rajeev|Ochudlo, Stanislaw|Ondo, William G.|Anderson, Karen E. 134 Improvements in Clinical Global Impression of Change With Deutetrabenazine Treatment in Tardive Dyskinesia From the ARM-TD and AIM-TD StudiesCNS Spectrums [10928529]. 23(1) , 2018.
Anderson, Karen E.|Davis, Mat D.|Factor, Stewart A.|Hauser, Robert A.|Jarskog, L. Fredrik|Jimenez-Shahed, Joohi|Kumar, Rajeev|FRCPC|Ochudlo, Stanislaw|Ondo, William G.|Fernandez, Hubert H. 149 Deutetrabenazine for the Treatment of Tardive Dyskinesia: Results From an Open-Label, Long-Term StudyCNS Spectrums [10928529]. 23(1) , 2018.
Anderson, Karen E.|Davis, Mat D.|Factor, Stewart A.|Hauser, Robert A.|Jarskog, L. Fredrik|Jimenez-Shahed, Joohi|Kumar, Rajeev|Ochudlo, Stanislaw|Ondo, William G.|Fernandez, Hubert H. 158 Long-Term Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia: Results From an Open-Label, Long-Term StudyCNS Spectrums [10928529]. 23(1) , 2018.
Lew, Mark F.|Brashear, Allison|Dashtipour, Khashayar|Isaacson, Stuart|Hauser, Robert A.|Maisonobe, Pascal|Snyder, Daniel|Ondo, William A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystoniaInternational Journal of Neuroscience [00207454]. 128(7) , 2018.
Gracies, Jean-Michel|Delgado, Mauricio R.|Hauser, Robert A.|Grimes, David A.|Picaut, Philippe|Mann, Amandeep|Om, Savary AbobotulinumtoxinA time to retreatment across indicationsToxicon [00410101]. 156, 2018.
Espay, A.J.|Hauser, R.A.|Isaacson, S.|Pahwa, R.|Truong, D.|Pappert, E.|Agro, A.|Fernandez, H.H. Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in subjects with Parkinson’s disease: preliminary results from the Phase-3 study dose-titration phaseParkinsonism and Related Disorders [13538020]. 46, 2018.
Charvin, Delphine|Medori, Rossella|Hauser, Robert A.|Rascol, Olivier Erratum: Therapeutic strategies for Parkinson disease: beyond dopaminergic drugsNature Reviews Drug Discovery [14741776]. 17(11) , 2018.
Hauser, Robert A. Help cure Parkinson’s disease: please don’t waste the Golden Yearnpj Parkinson's Disease [23738057]. 4(1) , 2018.
Hewitt, L. Arthur|Vernino, Steven|Biaggioni, Italo|Hauser, Robert A. Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with Parkinson DiseaseMovement Disorders Clinical Practice [23301619]. 5(6) , 2018.
Hauser, Robert A|Ellenbogen, Aaron|Khanna, Sarita|Gupta, Suneel|Modi, Nishit B Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s diseaseNeuropsychiatric Disease and Treatment [11766328]. Volume 14, 2018.
Fernandez, H.H.|Isaacson, S.|Espay, A.J.|Pahwa, R.|Truong, D.|Pappert, E.|Agro, A.|Hauser, R.A. Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF-episodes in subjects with Parkinson’s disease: preliminary results from the Phase-3 study dose titration phaseParkinsonism and Related Disorders [13538020]. 46, 2018.
Portillo, Ivan|Chen, Jack J.|Dashtipour, Khashayar|Han, Yi|Hauser, Robert A.|Tang, Jonathan Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-analysis and Mixed Treatment Comparison of Randomized TrialsThe Annals of Pharmacotherapy [10600280]. 52(12) , 2018.
Hauser, Robert A.|Truong, Daniel Tardive dyskinesia: Out of the shadowsJournal of the Neurological Sciences [0022510X]. 389, 2018.
Frei, Karen|Truong, Daniel D.|Fahn, Stanley|Jankovic, Joseph|Hauser, Robert A. The nosology of tardive syndromesJournal of the Neurological Sciences [0022510X]. 389, 2018.
Chahine, Lana M.|Weintraub, Daniel|Siderowf, Andrew|Trojanowski, John Q.|Shaw, Leslie M.|Tosun‐Turgut, Duygu|Tanner, Caroline M.|Schuff, Norbert|Coffey, Christopher S.|Caspell‐Garcia, Chelsea|Marek, Kenneth|Lasch, Shirley|Seibyl, John|Foroud, Tatiana|Jennings, Danna|Mollenhauer, Brit|Simuni, Tanya|Singleton, Andrew|Toga, Arthur W.|Arnedo, Vanessa|Frasier, Mark|Sherer, Todd|Chowdhury, Sohini|Poston, Kathleen|Kieburtz, Karl|Galasko, Doug The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohortAnnals of Clinical and Translational Neurology [23289503]. 5(12) , 2018.
Charvin, Delphine|Medori, Rossella|Hauser, Robert A.|Rascol, Olivier Therapeutic strategies for Parkinson disease: beyond dopaminergic drugsNature Reviews Drug Discovery [14741776]. 17(11) , 2018.
Jankovic, Joseph|Langston, Bill|Lyons, Kelly|Malaty, Irene|Mari, Zoltan|Marras, Connie|Miyasaki, Janis|Nutt, John"Jay"|Hauser, Robert|Pagan, Fernando|Parashos, Sotirios|Quinn, Joe|Salins, Naomi|Santiago, Anthony|Siderowf, Andrew|Simuni, Tanya|Simon, David|Singer, Carlos|Tarsy, Daniel|Bloem, Bastiaan|Brandabur, Melanie|Dahodwala, Nabila|Davis, Thomas|Dhall, Rohit|Gurevich, Tanya|Guttman, Mark|Parashos, Sotirios A.|Bloem, Bastiaan R.|Browner, Nina M.|Giladi, Nir|Gurevich, Tanya|Hausdorff, Jeffrey M.|He, Ying|Lyons, Kelly E.|Mari, Zoltan|Morgan, John C.|Post, Bart|Schmidt, Peter N.|Wielinski, Catherine L.|Wu, Samuel S. What predicts falls in Parkinson disease?: Observations from the Parkinson's Foundation registryNeurology: Clinical Practice [21630402]. 8(3) , 2018.
Hauser RA, Li R, Pérez A, Ren X, Weintraub D, Elm J, Goudreau JL, Morgan JC, Fang JY, Aminoff MJ, Christine CW, Dhall R, Umeh CC, Boyd JT, Stover N, Leehey M, Zweig RM, Nicholas AP, Bodis-Wollner I, Willis A, Kieburtz K, Tilley BC. Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson''s Disease: An Analysis of NET-PD LS1.Journal of Parkinson''s disease. 7(1) : 117-127, 2017.
Valdés EG, O''Connor ML, Uc EY, Hauser RA, Andel R, Edwards JD. Use, maintenance and dose effects of cognitive speed of processing training in Parkinson''s disease.The International journal of neuroscience. 127(10) : 841-848, 2017.
Pahwa R, Tanner CM, Hauser RA, Isaacson SH, Nausieda PA, Truong DD, Agarwal P, Hull KL, Lyons KE, Johnson R, Stempien MJ. ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.JAMA neurology. 74(8) : 941-949, 2017.
Hauser RA, Pahwa R, Tanner CM, Oertel W, Isaacson SH, Johnson R, Felt L, Stempien MJ. ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson''s Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study.Journal of Parkinson''s disease. 7(3) : 511-522, 2017.
Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isojärvi J, Jarskog LF, Jimenez-Shahed J, Kumar R, McEvoy JP, Ochudlo S, Ondo WG, Fernandez HH. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.The lancet. Psychiatry. 4(8) : 595-604, 2017.
Oertel W, Eggert K, Pahwa R, Tanner CM, Hauser RA, Trenkwalder C, Ehret R, Azulay JP, Isaacson S, Felt L, Stempien MJ. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson''s disease (EASE LID 3).Movement disorders : official journal of the Movement Disorder Society. , 2017.
Seeberger LC, Hauser RA. Valbenazine for the treatment of tardive dyskinesia.Expert opinion on pharmacotherapy. 18(12) : 1279-1287, 2017.
Biglan KM, Oakes D, Lang AE, Hauser RA, Hodgeman K, Greco B, Lowell J, Rockhill R, Shoulson I, Venuto C, Young D, Simuni T. A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III).Annals of clinical and translational neurology. 4(6) : 360-368, 2017.
Tilley BC, Mainous AG, Smith DW, McKee MD, Amorrortu RP, Alvidrez J, Diaz V, Ford ME, Fernandez ME, Hauser RA, Singer C, Landa V, Trevino A, DeSantis SM, Zhang Y, Daniels E, Tabor D, Vernon SW. Design of a cluster-randomized minority recruitment trial: RECRUIT.Clinical trials (London, England). 14(3) : 286-298, 2017.
Chou KL, Elm JJ, Wielinski CL, Simon DK, Aminoff MJ, Christine CW, Liang GS, Hauser RA, Sudarsky L, Umeh CC, Voss T, Juncos J, Fang JY, Boyd JT, Bodis-Wollner I, Mari Z, Morgan JC, Wills AM, Lee SL, Parashos SA. Factors associated with falling in early, treated Parkinson''s disease: The NET-PD LS1 cohort.Journal of the neurological sciences. 377: 137-143, 2017.
Stocchi F, Rascol O, Hauser RA, Huyck S, Tzontcheva A, Capece R, Ho TW, Sklar P, Lines C, Michelson D, Hewitt DJ. Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease.Neurology. 88(23) : 2198-2206, 2017.
Goetz CG, Stebbins GT, Chung KA, Nicholas AP, Hauser RA, Merkitch D, Stacy MA. Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson''s disease: A randomized, double-blind, placebo-controlled multicenter study.Movement disorders : official journal of the Movement Disorder Society. , 2017.
Olanow CW, Kieburtz K, Leinonen M, Elmer L, Giladi N, Hauser RA, Klepiskaya OS, Kreitzman DL, Lew MF, Russell DS, Kadosh S, Litman P, Friedman H, Linvah N, The P B Study Group F. A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson''s disease.Movement disorders : official journal of the Movement Disorder Society. 32(5) : 783-789, 2017.
Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, Burke J, Liang GS, O''Brien CF. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.The American journal of psychiatry. 174(5) : 476-484, 2017.
Fernandez HH, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Meltzer HY, Woods SW, Bega D, LeDoux MS, Shprecher DR, Davis C, Davis MD, Stamler D, Anderson KE. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study.Neurology. 88(21) : 2003-2010, 2017.
Simon DK, Wu C, Tilley BC, Lohmann K, Klein C, Payami H, Wills AM, Aminoff MJ, Bainbridge J, Dewey R, Hauser RA, Schaake S, Schneider JS, Sharma S, Singer C, Tanner CM, Truong D, Wei P, Wong PS, Yang T. Caffeine, creatine, GRIN2A and Parkinson''s disease progression.Journal of the neurological sciences. 375: 355-359, 2017.
White WB, Hauser RA, Rowse GJ, Ziemann A, Hewitt LA. Cardiovascular Safety of Droxidopa in Patients With Symptomatic Neurogenic Orthostatic Hypotension.The American journal of cardiology. 119(7) : 1111-1115, 2017.
Schapira AH, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, Kulisevsky J, Pahwa R, Poewe W, Anand R. Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.JAMA neurology. 74(2) : 216-224, 2017.
Tetrud J, Nausieda P, Kreitzman D, Liang GS, Nieves A, Duker AP, Hauser RA, Farbman ES, Ellenbogen A, Hsu A, Kell S, Khanna S, Rubens R, Gupta S. Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson''s disease.Journal of the neurological sciences. 373: 116-123, 2017.
Oakes, David|Young, Diony|Lang, Anthony E.|Rockhill, Rebecca|Venuto, Charles|Hodgeman, Karen|Greco, Brittany|Lowell, Jillian|Biglan, Kevin M.|Hauser, Robert A.|Simuni, Tanya|Shoulson, Ira A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY‐PD III)Annals of Clinical and Translational Neurology [23289503]. 4(6) , 2017.
Kreitzman, David L.|Giladi, Nir|Litman, Pninit|Friedman, Hadas|Linvah, Nurit|Hauser, Robert A.|Klepiskaya, Olga S.|Lew, Mark F.|Russell, David S.|Elmer, Lawrence|Kieburtz, Karl|the P2B Study Group, for|Olanow, C. Warren|Leinonen, Mika|Kadosh, Shaul A randomized trial of a low‐dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's diseaseMovement Disorders [08853185]. 32(5) , 2017.
Pahwa, Rajesh|Hauser, Robert A. ADS-5102 (Amantadine) Extended Release for Levodopa-Induced DyskinesiaArchives of Neurology [00039942]. 74(12) , 2017.
Pahwa, Rajesh|Tanner, Caroline M.|Hauser, Robert A.|Isaacson, Stuart H.|Nausieda, Paul A.|Truong, Daniel D.|Agarwal, Pinky|Hull, Keith L.|Lyons, Kelly E.|Johnson, Reed|Stempien, Mary Jean ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical TrialArchives of Neurology [00039942]. 74(8) , 2017.
Hauser, Robert A.|Pahwa, Rajesh|Tanner, Caroline M.|Oertel, Wolfgang|Isaacson, Stuart H.|Johnson, Reed|Felt, Larissa|Stempien, Mary Jean ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety StudyJournal of Parkinson's Disease [18777171]. 7(3) , 2017.
Schapira, Anthony H. V.|Fox, Susan H.|Hauser, Robert A.|Jankovic, Joseph|Jost, Wolfgang H.|Kenney, Christopher|Kulisevsky, Jaime|Pahwa, Rajesh|Poewe, Werner|Anand, Ravi Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical TrialArchives of Neurology [00039942]. 74(2) , 2017.
Simon, David K.|Wu, Cai|Tilley, Barbara C.|Lohmann, Katja|Klein, Christine|Payami, Haydeh|Wills, Anne-Marie|Aminoff, Michael J.|Bainbridge, Jacquelyn|Dewey, Richard|Hauser, Robert A.|Schaake, Susen|Schneider, Jay S.|Sharma, Saloni|Singer, Carlos|Tanner, Caroline M.|Truong, Daniel|Wei, Peng|Wong, Pei Shieen|Yang, Tianzhong Caffeine, creatine, GRIN2A and Parkinson's disease progressionJournal of the Neurological Sciences [0022510X]. 375, 2017.
White, William B.|Hauser, Robert A.|Rowse, Gerald J.|Ziemann, Adam|Hewitt, L. Arthur Cardiovascular Safety of Droxidopa in Patients With Symptomatic Neurogenic Orthostatic HypotensionAmerican Journal of Cardiology [00029149]. 119(7) , 2017.
Tetrud, James|Nausieda, Paul|Kreitzman, David|Liang, Grace S.|Nieves, Anette|Duker, Andrew P.|Hauser, Robert A.|Farbman, Eric S.|Ellenbogen, Aaron|Hsu, Ann|Kell, Sherron|Khanna, Sarita|Rubens, Robert|Gupta, Suneel Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's diseaseJournal of the Neurological Sciences [0022510X]. 373, 2017.
Tilley, Barbara C|Mainous, Arch G|Smith, Daniel W|McKee, M Diane|Amorrortu, Rossybelle P|Alvidrez, Jennifer|Diaz, Vanessa|Ford, Marvella E|Fernandez, Maria E|Hauser, Robert A|Singer, Carlos|Landa, Veronica|Trevino, Aron|DeSantis, Stacia M|Zhang, Yefei|Daniels, Elvan|Tabor, Derrick|Vernon, Sally W Design of a cluster-randomized minority recruitment trial: RECRUITClinical Trials [17407745]. 14(3) , 2017.
Anderson, Karen E|Stamler, David|Davis, Mat D|Factor, Stewart A|Hauser, Robert A|Isojärvi, Jouko|Jarskog, L Fredrik|Jimenez-Shahed, Joohi|Kumar, Rajeev|McEvoy, Joseph P|Ochudlo, Stanislaw|Ondo, William G|Fernandez, Hubert H Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trialThe Lancet Psychiatry [22150366]. 4(8) , 2017.
Chou, Kelvin L.|Elm, Jordan J.|Wielinski, Catherine L.|Simon, David K.|Aminoff, Michael J.|Christine, Chadwick W.|Liang, Grace S.|Hauser, Robert A.|Sudarsky, Lewis|Umeh, Chizoba C.|Voss, Tiffini|Juncos, Jorge|Fang, John Y.|Boyd, James T.|Bodis-Wollner, Ivan|Mari, Zoltan|Morgan, John C.|Wills, Anne-Marie|Lee, Stephen L.|Parashos, Sotirios A. Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohortJournal of the Neurological Sciences [0022510X]. 377, 2017.
Hauser, Robert A.|Factor, Stewart A.|Marder, Stephen R.|Knesevich, Mary Ann|Ramirez, Paul M.|Jimenez, Roland|Burke, Joshua|Liang, Grace S.|O’Brien, Christopher F. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive DyskinesiaAmerican Journal of Psychiatry [0002953X]. 174(5) , 2017.
Hauser, Robert A.|Li, Ruosha|Pérez, Adriana|Ren, Xuehan|Weintraub, Dan|Elm, Jordan|Goudreau, John L.|Morgan, John C.|Fang, John Y.|Aminoff, Michael J.|Christine, Chadwick W.|Dhall, Rohit|Umeh, Chizoba C.|Boyd, James T.|Stover, Natividad|Leehey, Maureen|Zweig, Richard M.|Nicholas, Anthony P.|Bodis-Wollner, Ivan|Willis, Allison|Kieburtz, Karl|Tilley, Barbara C. Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson’s Disease: An Analysis of NET-PD LS1Journal of Parkinson's Disease [18777171]. 7(1) , 2017.
Fernandez, Hubert H.|Factor, Stewart A.|Hauser, Robert A.|Jimenez-Shahed, Joohi|Ondo, William G.|Jarskog, L. Fredrik|Meltzer, Herbert Y.|Woods, Scott W.|Bega, Danny|LeDoux, Mark S.|Shprecher, David R.|Davis, Charles|Davis, Mat D.|Stamler, David|Anderson, Karen E. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD studyNeurology [00283878]. 88(21) , 2017.
Stocchi, Fabrizio|Rascol, Olivier|Hauser, Robert A.|Huyck, Susan|Tzontcheva, Anjela|Capece, Rachel|Ho, Tony W.|Sklar, Peter|Lines, Christopher|Michelson, David|Hewitt, David J. Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson diseaseNeurology [00283878]. 88(23) , 2017.
Azulay, Jean Philippe|Tanner, Caroline M.|Pahwa, Rajesh|Hauser, Robert A.|Trenkwalder, Claudia|Felt, Larissa|Stempien, Mary Jean|Oertel, Wolfgang|Eggert, Karla|Ehret, Reinhard|Isaacson, Stuart Randomized, placebo‐controlled trial of ADS‐5102 (amantadine) extended‐release capsules for levodopa‐induced dyskinesia in Parkinson's disease (EASE LID 3)Movement Disorders [08853185]. 32(12) , 2017.
Stacy, Mark A.|Chung, Kathryn A.|Goetz, Christopher G.|Stebbins, Glenn T.|Merkitch, Douglas|Nicholas, Anthony P.|Hauser, Robert A. Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double‐blind, placebo‐controlled multicenter studyMovement Disorders [08853185]. 32(9) , 2017.
Uc, Ergun Y.|O'Connor, Melissa L.|Hauser, Robert A.|Andel, Ross|Edwards, Jerri D.|Valdés, Elise G. Use, maintenance and dose effects of cognitive speed of processing training in Parkinson's diseaseInternational Journal of Neuroscience [00207454]. 127(10) , 2017.
Seeberger, Lauren C.|Hauser, Robert A. Valbenazine for the treatment of tardive dyskinesiaExpert Opinion on Pharmacotherapy [14656566]. 18(12) , 2017.
Wills AA, Elm JJ, Ye R, Chou KL, Parashos SA, Hauser RA, Bodis-Wollner I, Hinson VK, Christine CW, Schneider JS. Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1.Parkinsonism & related disorders. 33: 127-133, 2016.
Augustine EF, Dorsey ER, Hauser RA, Elm JJ, Tilley BC, Kieburtz KK. Communicating with participants during the conduct of multi-center clinical trials.Clinical trials (London, England). 13(6) : 592-596, 2016.
Hauser RA, Abler V, Eyal E, Eliaz RE. Efficacy of rasagiline in early Parkinson''s disease: a meta-analysis of data from the TEMPO and ADAGIO studies.The International Journal of Neuroscience. 126(10) : 942-6, 2016.
Rascol O, Hauser RA, Stocchi F, Fitzer-Attas CJ, Sidi Y, Abler V, Olanow CW. Long-term effects of rasagiline and the natural history of treated Parkinson''s disease.Movement disorders : official journal of the Movement Disorder Society. 31(10) : 1489-1496, 2016.
Hauser RA, Heritier S, Rowse GJ, Hewitt LA, Isaacson SH. Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension.Clinical neuropharmacology. 39(5) : 220-6, 2016.
Hauser RA, Olanow CW, Dzyngel B, Bilbault T, Shill H, Isaacson S, Dubow J, Agro A. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson''s disease.Movement disorders : official journal of the Movement Disorder Society. 31(9) : 1366-72, 2016.
François C, Rowse GJ, Hewitt LA, Vo P, Hauser RA. Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension.BMC neurology. 16(1) : 143, 2016.
Hauser RA, Slawek J, Barone P, Dohin E, Surmann E, Asgharnejad M, Bauer L. Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson''s disease.BMC neurology. 16: 90, 2016.
François C, Hauser RA, Aballéa S, Dorey J, Kharitonova E, Hewitt LA. Cost-effectiveness of droxidopa in patients with neurogenic orthostatic hypotension: post-hoc economic analysis of Phase 3 clinical trial data.Journal of Medical Economics. 19(5) : 515-25, 2016.
Weintraub D, Hauser RA, Elm JJ, Pagan F, Davis MD, Choudhry A. Rasagiline for mild cognitive impairment in Parkinson''s disease: A placebo-controlled trial.Movement Disorders : Official Journal of the Movement Disorder Society. 31(5) : 709-14, 2016.
LeWitt PA, Hauser RA, Grosset DG, Stocchi F, Saint-Hilaire MH, Ellenbogen A, Leinonen M, Hampson NB, DeFeo-Fraulini T, Freed MI, Kieburtz KD. A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson''s disease.Movement Disorders : Official Journal of the Movement Disorder Society. , 2016.
, Biglan KM, Shoulson I, Kieburtz K, Oakes D, Kayson E, Shinaman MA, Zhao H, Romer M, Young A, Hersch S, Penney J, Marder K, Paulsen J, Quaid K, Siemers E, Tanner C, Mallonee W, Suter G, Dubinsky R, Gray C, Nance M, Bundlie S, Radtke D, Kostyk S, Baic C, Caress J, Walker F, Hunt V, O''Neill C, Chouinard S, Factor S, Greenamyre T, Wood-Siverio C, Corey-Bloom J, Song D, Peavy G, Moskowitz C, Wesson M, Samii A, Bird T, Lipe H, Blindauer K, Marshall F, Zimmerman C, Goldstein J, Rosas D, Novak P, Caviness J, Adler C, Duffy A, Wheelock V, Tempkin T, Richman D, Seeberger L, Albin R, Chou KL, Racette B, Perlmutter JS, Perlman S, Bordelon Y, Martin W, Wieler M, Leavitt B, Raymond L, Decolongon J, Clarke L, Jankovic J, Hunter C, Hauser RA, Sanchez-Ramos J, Furtado S, Suchowersky O, Klimek ML, Guttman M, Sethna R, Feigin A, Cox M, Shannon B, Percy A, Dure L, Harrison M, Johnson W, Higgins D, Molho E, Nickerson C, Evans S, Hobson D, Singer C, Galvez-Jimenez N, Shannon K, Comella C, Ross C, Saint-Hilaire MH, Testa C, Rosenblatt A, Hogarth P, Weiner W, Como P, Kumar R, Cotto C, Stout J, Brocht A, Watts A, Eberly S, Weaver C, Foroud T, Gusella J, MacDonald M, Myers R, Fahn S, Shults C. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.JAMA Neurology. 73(1) : 102-10, 2016.
Han, Yi|Stevens, Andrea L.|Dashtipour, Khashayar|Hauser, Robert A.|Mari, Zoltan A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystoniaJournal of Neurology [03405354]. 263(4) , 2016.
LeWitt, Peter A.|Hauser, Robert A.|Grosset, Donald G.|Stocchi, Fabrizio|Saint-Hilaire, Marie-Helene|Ellenbogen, Aaron|Leinonen, Mika|Hampson, Neil B.|DeFeo-Fraulini, Tia|Freed, Martin I.|Kieburtz, Karl D. A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease: Inhaled Levodopa (CVT-301) for Fluctuating PDMovement Disorders [08853185]. 31(9) , 2016.
François, Clément|Rowse, Gerald J.|Hewitt, L. Arthur|Vo, Pamela|Hauser, Robert A. Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotensionBMC Neurology [14712377]. 16(1) , 2016.
Wills, Anne-Marie A.|Elm, Jordan J.|Ye, Rong|Chou, Kelvin L.|Parashos, Sotirios A.|Hauser, Robert A.|Bodis-Wollner, Ivan|Hinson, Vanessa K.|Christine, Chadwick W.|Schneider, Jay S. Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1Parkinsonism and Related Disorders [13538020]. 33, 2016.
Augustine, Erika F|Dorsey, E Ray|Hauser, Robert A|Elm, Jordan J|Tilley, Barbara C|Kieburtz, Karl K Communicating with participants during the conduct of multi-center clinical trialsClinical Trials [17407745]. 13(6) , 2016.
François, Clément|Hauser, Robert A.|Aballéa, Samuel|Dorey, Julie|Kharitonova, Elizaveta|Hewitt, L. Arthur Cost-effectiveness of droxidopa in patients with neurogenic orthostatic hypotension: post-hoc economic analysis of Phase 3 clinical trial dataJournal of Outcomes Research [13696998]. 19(5) , 2016.
Hauser, Robert A.|Heritier, Stephane|Rowse, Gerald J.|Hewitt, L. Arthur|Isaacson, Stuart H. Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic HypotensionClinical Neuropharmacology [03625664]. 39(5) , 2016.
Hauser, Robert A.|Abler, Victor|Eyal, Eli|Eliaz, Rom E. Efficacy of rasagiline in early Parkinson's disease: a meta-analysis of data from the TEMPO and ADAGIO studiesInternational Journal of Neuroscience [00207454]. 126(10) , 2016.
Weintraub, Daniel|Hauser, Robert A.|Davis, Matthew|Choudhry, Azhar Efficacy of rasagiline in PD patients with mild cognitive impairmentParkinsonism and Related Disorders [13538020]. 22, 2016.
Agro, Albert|Dubow, Jordan|Dzyngel, Bruce|Bilbault, Thierry|Giovinazzo, Anthony|Shill, Holly|Hauser, Robert Efficacy of sublingual apomorphine (APL-130277) for the treatment of OFF episodes in patients with Parkinson's diseaseParkinsonism and Related Disorders [13538020]. 22, 2016.
Agro, Albert|Dubow, Jordan|Dzyngel, Bruce|Bilbault, Thierry|Giovinazzo, Anthony|Shill, Holly|Hauser, Robert Efficacy of sublingual apomorphine (APL-130277) for the treatment of off episodes in patients with Parkinson's diseaseParkinsonism and Related Disorders [13538020]. 22, 2016.
Hauser, Robert A|Slawek, Jaroslaw|Barone, Paolo|Dohin, Elisabeth|Surmann, Erwin|Asgharnejad, Mahnaz|Bauer, Lars Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson’s diseaseBMC Neurology [14712377]. 16(1) , 2016.
Hauser, Robert A.|Olanow, C. Warren|Abler, Victor|Fitzer‐Attas, Cheryl J.|Stocchi, Fabrizio|Rascol, Olivier|Sidi, Yulia Long‐term effects of rasagiline and the natural history of treated Parkinson's diseaseMovement Disorders [08853185]. 31(10) , 2016.
Kumar, Rajeev|Hauser, Robert A.|Mostillo, Joseph|Dronamraju, Nalina|Graf, Ana|Merschhemke, Martin|Kenney, Christopher Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patientsInternational Journal of Neuroscience [00207454]. 126(1) , 2016.
Espay, Alberto J|LeWitt, Peter A|Hauser, Robert A|Merola, Aristide|Masellis, Mario|Lang, Anthony E Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targetsLancet Neurology [14744422]. 15(9) , 2016.
Weintraub, Daniel|Elm, Jordan J.|Pagan, Fernando|Hauser, Robert A.|Davis, Matthew D.|Choudhry, Azhar Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo‐controlled trialMovement Disorders [08853185]. 31(5) , 2016.
Hauser, Robert A.|Olanow, C. Warren|Dzyngel, Bruce|Bilbault, Thierry|Shill, Holly|Isaacson, Stuart|Dubow, Jordan|Agro, Albert Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease: Sublingual Apomorphine Film Strip in PDMovement Disorders [08853185]. 31(9) , 2016.
Hauser, Robert A.|Eliaz, Rom|Eyal, Eli|Abler, Victor|Schilling, Traci Symptomatic efficacy of rasagiline in early PD: A meta-analysisParkinsonism and Related Disorders [13538020]. 22, 2016.
Hauser RA, Stocchi F, Rascol O, Huyck SB, Capece R, Ho TW, Sklar P, Lines C, Michelson D, Hewitt D. Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons Learned.JAMA Neurology. 72(12) : 1491-500, 2015.
O''Brien CF, Jimenez R, Hauser RA, Factor SA, Burke J, Mandri D, Castro-Gayol JC. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study.Movement Disorders : Official Journal of the Movement Disorder Society. 30(12) : 1681-7, 2015.
Simon DK, Wu C, Tilley BC, Wills AM, Aminoff MJ, Bainbridge J, Hauser RA, Schneider JS, Sharma S, Singer C, Tanner CM, Truong D, Wong PS. Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine.Clinical Neuropharmacology. 38(5) : 163-9, 2015.
Hauser RA. α-Synuclein in Parkinson''s disease: getting to the core of the matter.The Lancet. Neurology. 14(8) : 785-6, 2015.
Pahwa R, Tanner CM, Hauser RA, Sethi K, Isaacson S, Truong D, Struck L, Ruby AE, McClure NL, Went GT, Stempien MJ. Amantadine extended release for levodopa-induced dyskinesia in Parkinson''s disease (EASED Study).Movement Disorders : Official Journal of the Movement Disorder Society. 30(6) : 788-95, 2015.
Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson''s disease (nOH306B).Movement Disorders : Official Journal of the Movement Disorder Society. 30(5) : 646-54, 2015.
Poewe W, Hauser RA, Lang A. Effects of rasagiline on the progression of nonmotor scores of the MDS-UPDRS.Movement Disorders : Official Journal of the Movement Disorder Society. 30(4) : 589-92, 2015.
Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F, Lew MF, Odin P, Steiger M, Yakupov EZ, Chouinard S, Suchowersky O, Dubow J, Hall CM, Chatamra K, Robieson WZ, Benesh JA, Espay AJ. Levodopa-carbidopa intestinal gel in advanced Parkinson''s disease: final 12-month, open-label results.Movement Disorders : Official Journal of the Movement Disorder Society. 30(4) : 500-9, 2015.
Hauser RA. Initial choice of medication has little effect on short-term or long-term outcome for most patients with Parkinson''s disease.Evidence-based Medicine. 20(1) : 17, 2015.
Wechsler R, Hauser RA, French J. Who is helping whom? Manuscript support and transfer of value.Annals of Neurology. 77(2) : 353-5, 2015.
Ruby, April E.|McClure, Natalie L.|Went, Gregory T.|Stempien, Mary Jean|Pahwa, Rajesh|Hauser, Robert A.|Struck, Lynn|Sethi, Kapil|Tanner, Caroline M.|Isaacson, Stuart|Truong, Daniel Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study)Movement Disorders [08853185]. 30(6) , 2015.
Simon, David K.|Wu, Cai|Tilley, Barbara C.|Wills, Anne-Marie|Aminoff, Michael J.|Bainbridge, Jacquelyn|Hauser, Robert A.|Schneider, Jay S.|Sharma, Saloni|Singer, Carlos|Tanner, Caroline M.|Truong, Daniel|Wong, Pei Shieen Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With CreatineClinical Neuropharmacology [03625664]. 38(5) , 2015.
Seeberger, Lauren C|Hauser, Robert A Carbidopa levodopa enteral suspensionExpert Opinion on Pharmacotherapy [14656566]. 16(18) , 2015.
Hauser, Robert A.|Hewitt, L. Arthur|Rowse, Gerry|Isaacson, Stuart|Lisk, Jerome P. Droxidopa for the S hort‐ T erm T reatment of S ymptomatic N eurogenic O rthostatic H ypotension in P arkinson's D isease (n OH 306 B )Movement Disorders [08853185]. 30(5) , 2015.
Kieburtz, Karl|Tilley, Barbara C.|Elm, Jordan J.|Babcock, Debra|Hauser, Robert|Ross, G. Webster|Augustine, Alicia H.|Augustine, Erika U.|Aminoff, Michael J.|Bodis-Wollner, Ivan G.|Boyd, James|Cambi, Franca|Chou, Kelvin|Christine, Chadwick W.|Cines, Michelle|Dahodwala, Nabila|Derwent, Lorelei|Dewey, Richard B.|Hawthorne, Katherine|Houghton, David J.|Kamp, Cornelia|Leehey, Maureen|Lew, Mark F.|Liang, Grace S. Lin|Luo, Sheng T.|Mari, Zoltan|Morgan, John C.|Parashos, Sotirios|Pérez, Adriana|Petrovitch, Helen|Rajan, Suja|Reichwein, Sue|Roth, Jessie Tatsuno|Schneider, Jay S.|Shannon, Kathleen M.|Simon, David K.|Simuni, Tanya|Singer, Carlos|Sudarsky, Lewis|Tanner, Caroline M.|Umeh, Chizoba C.|Williams, Karen|Wills, Anne-Marie Effect of Creatine Monohydrate on Clinical Progression in Patients With Parkinson Disease: A Randomized Clinical TrialJournal of the American Medical Association [00987484]. 313(6) , 2015.
Lang, Anthony|Poewe, Werner|Hauser, Robert A. Effects of rasagiline on the progression of nonmotor scores of the MDS‐UPDRSMovement Disorders [08853185]. 30(4) , 2015.
Hauser, R.A.|Abler, V.|Eliaz, R.E.|Eyal, E.|Choudhry, A. Efficacy of rasagiline in early Parkinson’s disease (PD): a meta-analysis of data from the tempo and adagio studiesJournal of the Neurological Sciences [0022510X]. 357, 2015.
Weintraub, D.|Hauser, R.A.|Davis, M.|Choudhry, A. Efficacy of rasagiline in patients with Parkinson’s disease and mild cognitive impairment: results from moderato, a 24-week randomized, double-blind, placebo-controlled trialJournal of the Neurological Sciences [0022510X]. 357, 2015.
Stegemöller, Elizabeth L.|Schmidt, Peter|Hass, Chris|Malaty, Irene|Okun, Michael S.|Bransabur, Melanie|Bloem, Bastiaan|Cho, Catherine|Santiago, Anthony|Gurevich, Tanya|Guttman, Mark|Hauser, Robert|Jankovic, Jospeoh|Lyons, Kelly|Mari, Zoltan|Morgan, John|Nutt, John|Parashos, Sotirios|Siderowf, Andrew|Simuni, Tanya|Tarsy, Daniel|Davis, Thomas|Miyasaki, Janis|Cheng, Eric|Giraldi, Nir|Marsh, Laura|Nelson, Eugene|Zamundio, Jorge How Should Pushing Off or the Use of Assistive Devices Be Incorporated in the Timed Up and Go for Persons With Parkinson Disease?Archives of Physical Medicine and Rehabilitation [00039993]. 96(9) , 2015.
Hauser, Robert A Initial choice of medication has little effect on short-term or long-term outcome for most patients with Parkinson's diseaseEvidence-Based Medicine [13565524]. 20(1) , 2015.
Fung, Victor S.C.|Odin, Per|Espay, Alberto J.|Steiger, Malcolm|Suchowersky, Oksana|Lang, Anthony E.|Chouinard, Sylvain|Lew, Mark F.|Yakupov, Eduard Z.|Standaert, David G.|Klostermann, Fabian|Fernandez, Hubert H.|Dubow, Jordan|Hall, Coleen M.|Chatamra, Krai|Robieson, Weining Z.|Benesh, Janet A.|Hauser, Robert A. Levodopa‐carbidopa intestinal gel in advanced Parkinson's disease: Final 12‐month, open‐label resultsMovement Disorders [08853185]. 30(4) , 2015.
Factor, Stewart A.|Mandri, Daniel|Castro‐Gayol, Julio C.|O'Brien, Christopher F.|Jimenez, Roland|Burke, Joshua|Hauser, Robert A. NBI‐98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double‐blind, placebo‐controlled studyMovement Disorders [08853185]. 30(12) , 2015.
Bega, Danny|Kim, Soeun|Zhang, Yunxi|Elm, Jordan|Schneider, Jay|Hauser, Robert|Fraser, Andy|Simuni, Tanya Predictors of Functional Decline in Early Parkinson’s Disease: NET-PD LS1 CohortJournal of Parkinson's Disease [18777171]. 5(4) , 2015.
Hauser, Robert A.|Stocchi, Fabrizio|Rascol, Olivier|Huyck, Susan B.|Capece, Rachel|Ho, Tony W.|Sklar, Peter|Lines, Christopher|Michelson, David|Hewitt, David Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons LearnedArchives of Neurology [00039942]. 72(12) , 2015.
Wechsler, Robert|Hauser, Robert A.|French, Jacqueline Who is helping whom? Manuscript support and transfer of valueAnnals of Neurology [03645134]. 77(2) , 2015.
Hauser, Robert A α-Synuclein in Parkinson's disease: getting to the core of the matterLancet Neurology [14744422]. 14(8) , 2015.
Bajaj N, Hauser RA, Seibyl J, Kupsch A, Plotkin M, Chen C, Grachev ID. Association between Hoehn and Yahr, Mini-Mental State Examination, age, and clinical syndrome predominance and diagnostic effectiveness of ioflupane I 123 injection (DaTSCAN™) in subjects with clinically uncertain parkinsonian syndromes.Alzheimer''s Research & Therapy. 6: 67, 2014.
Hauser RA, Isaacson S, Clinch T. Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection.Parkinsonism & Related Disorders. 20(11) : 1171-6, 2014.
Seibyl JP, Kupsch A, Booij J, Grosset DG, Costa DC, Hauser RA, Darcourt J, Bajaj N, Walker Z, Marek K, McKeith I, O''Brien JT, Tatsch K, Tolosa E, Dierckx RA, Grachev ID. Individual-reader diagnostic performance and between-reader agreement in assessment of subjects with Parkinsonian syndrome or dementia using 123I-ioflupane injection (DaTscan) imaging.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 55(8) : 1288-96, 2014.
Goldman SM, Kamel F, Ross GW, Jewell SA, Marras C, Hoppin JA, Umbach DM, Bhudhikanok GS, Meng C, Korell M, Comyns K, Hauser RA, Jankovic J, Factor SA,. Peptidoglycan recognition protein genes and risk of Parkinson''s disease.Mov Disord. 29(9) : 1171-80, 2014.
Hauser RA, Olanow CW, Kieburtz KD, Pourcher E, Docu-Axelerad A, Lew M, Kozyolkin O, Neale A, Resburg C, Meya U, Kenney C, Bandak S. Tozadenant (SYN115) in patients with Parkinson''s disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial.The Lancet. Neurology. 13(8) : 767-76, 2014.
Cicchetti F, Lacroix S, Cisbani G, Vallières N, Saint-Pierre M, St-Amour I, Tolouei R, Skepper J, Hauser R, Mantovani D, Barker R, Freeman T. Mutant huntingtin is present in neuronal grafts in Huntington''s disease patients.Ann Neurol. 76(1) : 31-42, 2014.
Hauser RA, Silver D, Choudhry A, Eyal E, Isaacson S, for the ANDANTE study investigators. Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson’s diseaseMov Disord. 29(8) : 1028-34, 2014.
Hauser RA, Silver D, Choudhry A, Eyal E, Isaacson S. Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson''s disease.Movement Disorders : Official Journal of the Movement Disorder Society. 29(8) : 1028-34, 2014.
The Parkinson Study Group QE3 Investigators (including Hauser RA). A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of Benefit.JAMA Neurol. 71(5) : 543-52, 2014.
Hauser RA, Gordon MF, Mizuno Y, Poewe W, Barone P, Schapira AH, Rascol O, Debieuvre C, Fräßdorf M. Minimal clinically important difference in Parkinson''s disease as assessed in pivotal trials of pramipexole extended release.Parkinson''s Disease. 2014: 467131, 2014.
Hauser RA, Schapira AH, Barone P, Mizuno Y, Rascol O, Busse M, Debieuvre C, Fraessdorf M, Poewe W. Pramipexole ER Studies Group.Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson''s disease.Eur J Neurol. 21(5) : 736-43, 2014.
Low PA, Robertson D, Gilman S, Kaufmann H, Singer W, Biaggioni I, Freeman R, Perlman S, Hauser RA, Cheshire W, Lessig S, Vernino S, Mandrekar J,. Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial.Lancet Neurol. 13(3) : 268-75, 2014.
Hauser RA, Gordon MF, Mizuno Y, Poewe W, Barone P, Schapira AH, Rascol O, Debieuvre C, Fräßdorf M. Minimal clinically important difference in Parkinson''s disease as assessed in pivotal trials of pramipexole extended release.Parkinsons Dis. , 2014.
Pahwa R, Lyons KE, Hauser RA, Fahn S, Jankovic J, Pourcher E, Hsu A, O''Connell M, Kell S, Gupta S. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson''s disease.Parkinsonism & Related Disorders. 20(2) : 142-8, 2014.
Kremens D, Hauser RA, Dorsey ER. An update on Parkinson''s disease: improving patient outcomes.The American Journal of Medicine. 127(1) : S3, 2014.
Han, Y.|Stevens, A.|Dashtipour, K.|Hauser, R.|Mari, Z. A Mixed Treatment Comparison (Mtc) To Compare The Efficacy Of Botulinum Toxin Type A Treatments For Cervical DystoniaValue in Health [10983015]. 17(3) , 2014.
Beal, M. Flint|Oakes, David|Shoulson, Ira|Henchcliffe, Claire|Galpern, Wendy R.|Haas, Richard|Juncos, Jorge L.|Nutt, John G.|Voss, Tiffini Smith|Ravina, Bernard|Shults, Clifford M.|Helles, Karen|Snively, Victoria|Lew, Mark F.|Griebner, Brian|Watts, Arthur|Gao, Shan|Pourcher, Emmanuelle|Bond, Louisette|Kompoliti, Katie|Agarwal, Pinky|Sia, Cherissa|Jog, Mandar|Cole, Linda|Sultana, Munira|Kurlan, Roger|Richard, Irene|Deeley, Cheryl|Waters, Cheryl H.|Figueroa, Angel|Arkun, Ani|Brodsky, Matthew|Ondo, William G.|Hunter, Christine B.|Jimenez-Shahed, Joohi|Palao, Alicia|Miyasaki, Janis M.|So, Julie|Tetrud, James|Reys, Liza|Smith, Katharine|Singer, Carlos|Blenke, Anita|Russell, David S.|Cotto, Candace|Friedman, Joseph H.|Lannon, Margaret|Zhang, Lin|Drasby, Edward|Kumar, Rajeev|Subramanian, Thyagarajan|Ford, Donna Stuppy|Grimes, David A.|Cote, Diane|Conway, Jennifer|Siderowf, Andrew D.|Evatt, Marian Leslie|Sommerfeld, Barbara|Lieberman, Abraham N.|Okun, Michael S.|Rodriguez, Ramon L.|Merritt, Stacy|Swartz, Camille Louise|Martin, W. R. Wayne|King, Pamela|Stover, Natividad|Guthrie, Stephanie|Watts, Ray L.|Ahmed, Anwar|Fernandez, Hubert H.|Winters, Adrienna|Mari, Zoltan|Dawson, Ted M.|Dunlop, Becky|Feigin, Andrew S.|Shannon, Barbara|Nirenberg, Melissa Jill|Ogg, Mattson|Ellias, Samuel A.|Thomas, Cathi-Ann|Frei, Karen|Bodis-Wollner, Ivan|Glazman, Sofya|Mayer, Thomas|Hauser, Robert A.|Pahwa, Rajesh|Langhammer, April|Ranawaya, Ranjit|Derwent, Lorelei|Sethi, Kapil D.|Farrow, Buff|Prakash, Rajan|Litvan, Irene|Robinson, Annette|Sahay, Alok|Gartner, Maureen|Hinson, Vanessa K.|Markind, Samuel|Pelikan, Melisa|Perlmutter, Joel S.|Hartlein, Johanna|Molho, Eric|Evans, Sharon|Adler, Charles H.|Duffy, Amy|Lind, Marlene|Elmer, Lawrence|Davis, Kathy|Spears, Julia|Wilson, Stephanie|Leehey, Maureen A.|Hermanowicz, Neal|Niswonger, Shari|Shill, Holly A.|Obradov, Sanja|Rajput, Alex|Cowper, Marilyn|Lessig, Stephanie|Song, David|Fontaine, Deborah|Zadikoff, Cindy|Williams, Karen|Blindauer, Karen A.|Bergholte, Jo|Propsom, Clara Schindler|Stacy, Mark A.|Field, Joanne|Mihaila, Dragos|Chilton, Mark|Uc, Ergun Y.|Sieren, Jeri|Simon, David K.|Kraics, Lauren|Silver, Althea|Boyd, James T.|Hamill, Robert W.|Ingvoldstad, Christopher|Young, Jennifer|Thomas, Karen|Kostyk, Sandra K.|Wojcieszek, Joanne|Pfeiffer, Ronald F.|Panisset, Michel|Beland, Monica|Reich, Stephen G.|Cines, Michelle|Zappala, Nancy|Rivest, Jean|Zweig, Richard|Lumina, L. Pepper|Hilliard, Colette Lynn|Grill, Stephen|Kellermann, Marye|Tuite, Paul|Rolandelli, Susan|Kang, Un Jung|Young, Joan|Rao, Jayaraman|Cook, Maureen M.|Severt, Lawrence|Boyar, Karyn A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of BenefitArchives of Neurology [00039942]. 71(5) , 2014.
Kremens, Daniel|Hauser, Robert A.|Dorsey, E. Ray An Update on Parkinson's Disease: Improving Patient OutcomesThe American Journal of Medicine Supplements [00029343]. 127(1) , 2014.
Bajaj, Nin|Hauser, Robert A|Seibyl, John|Kupsch, Andreas|Plotkin, Michail|Chen, Chris|Grachev, Igor D Association between Hoehn and Yahr, Mini-Mental State Examination, age, and clinical syndrome predominance and diagnostic effectiveness of ioflupane I 123 injection (DaTSCANTM) in subjects with clinically uncertain parkinsonian syndromesAlzheimer's Research and Therapy [17589193]. 6(5-8) , 2014.
LeWitt, Peter A.|Chen, Dan|Lissin, Dmitri|Zomorodi, Katie|Cundy, Kenneth C.|Huff, F. Jacob|Hauser, Robert A. Double‐blind study of the actively transported levodopa prodrug XP21279 in Parkinson's diseaseMovement Disorders [08853185]. 29(1) , 2014.
Hauser, Robert A.|Hewitt, L. Arthur|Isaacson, Stuart Droxidopa in Patients with Neurogenic Orthostatic Hypotension Associated with Parkinson's Disease (NOH306A)Journal of Parkinson's Disease [18777171]. 4(1) , 2014.
Low, Phillip A|Robertson, David|Gilman, Sid|Kaufmann, Horacio|Singer, Wolfgang|Biaggioni, Italo|Freeman, Roy|Perlman, Susan|Hauser, Robert A|Cheshire, William|Lessig, Stephanie|Vernino, Steven|Mandrekar, Jay|Dupont, William D|Chelimsky, Thomas|Galpern, Wendy R Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trialLancet Neurology [14744422]. 13(3) , 2014.
Seibyl, John P.|Kupsch, Andreas|Booij, Jan|Grosset, Donald G.|Costa, Durval C.|Hauser, Robert A.|Darcourt, Jacques|Bajaj, Nin|Walker, Zuzana|Marek, Kenneth|McKeith, Ian|O’Brien, John T.|Tatsch, Klaus|Tolosa, Eduardo|Dierckx, Rudi A.|Grachev, Igor D. Individual-Reader Diagnostic Performance and Between-Reader Agreement in Assessment of Subjects with Parkinsonian Syndrome or Dementia Using 123 I-Ioflupane Injection (DaTscan) ImagingJournal of Nuclear Medicine [01615505]. 55(8) , 2014.
Hauser, R. A.|Schapira, A. H. V.|Barone, P.|Mizuno, Y.|Rascol, O.|Busse, M.|Debieuvre, C.|Fraessdorf, M.|Poewe, W. Long‐term safety and sustained efficacy of extended‐release pramipexole in early and advanced P arkinson's diseaseEuropean Journal of Neurology [13515101]. 21(5) , 2014.
Hauser, Robert A.|Gordon, Mark Forrest|Mizuno, Yoshikuni|Poewe, Werner|Barone, Paolo|Schapira, Anthony H.|Rascol, Olivier|Debieuvre, Catherine|Fräßdorf, Mandy Minimal Clinically Important Difference in Parkinson’s Disease as Assessed in Pivotal Trials of Pramipexole Extended ReleaseParkinson's Disease [20908083]. 2014, 2014.
Nutt, J.G.|Siderowf, A.D.|Guttman, M.|Schmidt, P.N.|Zamudio, J.I.|Wu, S.S.|Okun, M.S.|Simuni, T.|Parashos, S.A.|Dahodwala|Davis, T.L.|Giladi, N.|Gurevich, T.|Hauser, R.A.|Jankovic, J.|Lyons, K.E.|Marsh, L.|Miyasaki, J.M.|Morgan, J.C.|Santiago, A.J.|Tarsy, D.|Mari, Z.|Malaty, I.A.|Nelson, E.C. Mobility, mood and site of care impact health related quality of life in Parkinson's diseaseParkinsonism and Related Disorders [13538020]. 20(3) , 2014.
Hauser, Robert A.|Barker, Roger A.|Tolouei, Ranna|Mantovani, Diego|Cisbani, Giulia|Vallières, Nicolas|Saint‐Pierre, Martine|St‐Amour, Isabelle|Cicchetti, Francesca|Lacroix, Steve|Freeman, Thomas B.|Skepper, Jeremy N. Mutant huntingtin is present in neuronal grafts in huntington disease patientsAnnals of Neurology [03645134]. 76(1) , 2014.
Hoppin, Jane A.|Tanner, Caroline M.|Jewell, Sarah A.|Factor, Stewart A.|Kamel, Freya|Sandler, Dale P.|Hauser, Robert A.|Bhudhikanok, Grace S.|Meng, Cheryl|Korell, Monica|Comyns, Kathleen|Langston, J. William|Lyons, Kelly E.|Marras, Connie|Goldman, Samuel M.|Umbach, David M.|Jankovic, Joseph|Bressman, Susan|Ross, G. Webster Peptidoglycan recognition protein genes and risk of Parkinson's diseaseMovement Disorders [08853185]. 29(9) , 2014.
Mari, Zoltan|Dashtipour, Khashayar|Han, Yi|Stevens, Andrea|Lomax, Kathleen G.|Hauser, Robert Poster 350 A Random Effect Mixed Treatment Comparison (MTC) to Compare the Efficacy of Botulinum Toxin Type A Treatments for Cervical DystoniaPM&R [19341482]. 6(9S) , 2014.
Pahwa, Rajesh|Lyons, Kelly E.|Hauser, Robert A.|Fahn, Stanley|Jankovic, Joseph|Pourcher, Emmanuelle|Hsu, Ann|O'Connell, Martin|Kell, Sherron|Gupta, Suneel Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's diseaseParkinsonism and Related Disorders [13538020]. 20(2) , 2014.
Silver, Dee|Hauser, Robert A.|Eyal, Eli|Choudhry, Azhar|Isaacson, Stuart Randomized, controlled trial of rasagiline as an add‐on to dopamine agonists in Parkinson's diseaseMovement Disorders [08853185]. 29(8) , 2014.
Hauser, Robert A.|Isaacson, Stuart|Clinch, Thomas Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injectionParkinsonism and Related Disorders [13538020]. 20(11) , 2014.
Hauser, Robert A|Olanow, C Warren|Kieburtz, Karl D|Pourcher, Emmanuelle|Docu-Axelerad, Any|Lew, Mark|Kozyolkin, Olexandr|Neale, Ann|Resburg, Chris|Meya, Uwe|Kenney, Christopher|Bandak, Stephen Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trialLancet Neurology [14744422]. 13(8) , 2014.
Lewitt PA, Huff FJ, Hauser RA, Chen D, Lissin D, Zomorodi K, Cundy KC. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson''s disease.Movement Disorders : Official Journal of the Movement Disorder Society. , 2013.
Hauser RA, Hewitt LA, Isaacson S. Droxidopa in Patients with Neurogenic Orthostatic Hypotension Associated with Parkinson''s Disease (NOH306A).Journal of Parkinson''s disease. : 57-65, 2013.
Stocchi F, Rascol O, Destee A, Hattori N, Hauser RA, Lang AE, Poewe W, Stacy M, Tolosa E, Gao H, Nagel J, Merschhemke M, Graf A, Kenney C, Trenkwalder C. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.Movement Disorders : Official Journal of the Movement Disorder Society. 28(13) : 1838-46, 2013.
Bajaj N, Hauser RA, Grachev ID. Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes.Journal of Neurology, Neurosurgery, and psychiatry. 84(11) : 1288-95, 2013.
The Parkinson Study Group (including Hauser RA). Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson''s disease (STEADY-PD)Mov Disord. 28(13) : 1823-31, 2013.
Nutt JG, Siderowf AD, Guttman M, Schmidt PN, Zamudio JI, Wu SS, Okun MS, Simuni T, Parashos SA, Dahodwala NA, Davis TL, Giladi N, Gurevich T, Hauser RA, Jankovic J, Lyons KE, Marsh L, Miyasaki JM, Morgan JC, Santiago AJ, Tarsy D, Mari Z, Malaty IA, Nelson EC. Mobility, mood and site of care impact health related quality of life in Parkinson''s disease.Parkinsonism & Related Disorders. , 2013.
Edwards JD, Hauser RA, O''Connor ML, Valdés EG, Zesiewicz TA, Uc EY. Randomized trial of cognitive speed of processing training in Parkinson disease.Neurology. 81(15) : 1284-90, 2013.
Kumar R, Hauser RA, Mostillo J, Dronamraju N, Graf A, Merschhemke M, Kenney C. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson''s disease patients.The International Journal of Neuroscience. , 2013.
Factor SA, Wolski K, Togasaki DM, Huyck S, Cantillon M, Ho TW, Hauser RA, Pourcher E. Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson''s disease.Movement Disorders : Official Journal of the Movement Disorder Society. 28(6) : 817-20, 2013.
Hauser RA, Hsu A, Kell S, Espay AJ, Sethi K, Stacy M, Ondo W, O''Connell M, Gupta S. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson''s disease and motor fluctuations: a phase 3 randomised, double-blind trial.Lancet neurology. 12(4) : 346-56, 2013.
Fernandez HH, Vanagunas A, Odin P, Espay AJ, Hauser RA, Standaert DG, Chatamra K, Benesh J, Pritchett Y, Hass SL, Lenz RA. Levodopa-carbidopa intestinal gel in advanced Parkinson''s disease open-label study: interim results.Parkinsonism & related disorders. 19(3) : 339-45, 2013.
Goetz CG, Stebbins GT, Chung KA, Hauser RA, Miyasaki JM, Nicholas AP, Poewe W, Seppi K, Rascol O, Stacy MA, Nutt JG, Tanner CM, Urkowitz A, Jaglin JA, Ge S. Which dyskinesia scale best detects treatment response?Movement disorders : official journal of the Movement Disorder Society. 28(3) : 341-6, 2013.
Hauser RA, Truong D, Hubble J, Coleman C, Beffy JL, Chang S, Picaut P. AbobotulinumtoxinA (Dysport) dosing in cervical dystonia: an exploratory analysis of two large open-label extension studies.Journal of neural transmission (Vienna, Austria : 1996). 120(2) : 299-307, 2013.
Cisbani G, Freeman TB, Soulet D, Saint-Pierre M, Gagnon D, Parent M, Hauser RA, Barker RA, Cicchetti F. Striatal allografts in patients with Huntington''s disease: impact of diminished astrocytes and vascularization on graft viability.Brain : A Journal of Neurology. 136(2) : 433-43, 2013.
HORIZON Investigators of the Huntington Study Group and European Huntington''s Disease Network. A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington diseaseJAMA Neurol. 70(1) : 25-33, 2013.
Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, Debieuvre C, Fraessdorf M, Poewe W. Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson''s disease.European journal of neurology : the official journal of the European Federation of Neurological Societies. 20(1) : 50-6, 2013.
Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, Debieuvre C, Fraessdorf M, Poewe W. Success rate, efficacy, and safety/tolerability of overnight switching from immediate- to extended-release pramipexole in advanced Parkinson''s disease.European journal of neurology : the official journal of the European Federation of Neurological Societies. 20(1) : 180-7, 2013.
Standaert, D.G.|Fernandez, H.H.|Odin, P.|Hauser, R.A.|Espay, A.J.|Steiger, M.|Chouinard, S.|Suchowersky, O.|Yakupov, E.|Merikle, E.P.|Robieson, W.Z.|Chatamra, K.|Benesh, J. A long-term, open-label study of levodopa–/INS;carbidopa intestinal gel in advanced Parkinson's disease patients: Functional and health-related quality-of-life endpointsJournal of the Neurological Sciences [0022510X]. 333, 2013.
Espay, A.J.|Odin, P.|Fernandez, H.H.|Hauser, R.A.|Standaert, D.G.|Lang, A.E.|Fung, V.S.|Klostermann, F.|Robieson, W.Z.|Chatamra, K.|Benesh, J. A long-term, open-label study of levodopa–/INS;carbidopa intestinal gel in advanced Parkinson's disease patients: safety and motor-symptom endpointsJournal of the Neurological Sciences [0022510X]. 333, 2013.
Hauser, R.A.|Olanow, C.W.|Kieburtz, K.D.|Neale, A.|Resburg, C.|Meya, U.|Bankak, S.I. A phase 2, placebo-controlled, randomized, double-blind trial of tozadenant (Syn-115) in patients with Parkinson's disease with wearing-off fluctuations on levodopaJournal of the Neurological Sciences [0022510X]. 333, 2013.
Hubble, J.|Hauser, R.|Coleman, C.|Yair, J.|Beffy, J.|Picaut, P. Abobotulinumtoxin A dosing in cervical dystonia: An analysis of two large open-label extension studiesToxicon [00410101]. 68, 2013.
Hauser, Robert A.|Truong, Daniel|Hubble, Jean|Coleman, Chandra|Beffy, Jean-Luc|Chang, Stephen|Picaut, Philippe AbobotulinumtoxinA (Dysport) dosing in cervical dystonia: an exploratory analysis of two large open-label extension studiesJournal of Neural Transmission [03009564]. 120(2) , 2013.
Stocchi, Fabrizio|Trenkwalder, Claudia|Nagel, Jennifer|Merschhemke, Martin|Graf, Ana|Destee, Alain|Gao, Haitao|Kenney, Christopher|Lang, Anthony E.|Rascol, Olivier|Tolosa, Eduardo|Stacy, Mark|Poewe, Werner|Hattori, Nobutaka|Hauser, Robert A. AFQ056 in Parkinson patients with levodopa‐induced dyskinesia: 13‐week, randomized, dose‐finding studyMovement Disorders [08853185]. 28(13) , 2013.
Bajaj, Nin|Hauser, Robert A|Grachev, Igor D Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with ( 123 I) ioflupane in diagnosis of parkinsonian syndromesJournal of Neurology, Neurosurgery and Psychiatry [00223050]. 84(11) , 2013.
Grachev, I.|Sherwin, P.|Lane, D.|Moreno, E.|Freid, J.|Bajaj, N.|Hauser, R.A.|Seibyl, J.|Grosset, D.G.|Marek, K. DaTSCAN™ (ioflupane I 123 injection), a radiopharmaceutical indicated for visualization of the striatal dopamine transporter using SPECT: Safety profile reviewJournal of the Neurological Sciences [0022510X]. 333, 2013.
Isaacson, S.|Silver, D.|Choudhry, A.|Hauser, R.A. Efficacy, safety and tolerability of rasagiline as an add-on therapy to dopamine agonists in early Parkinson's disease: The ANDANTE studyJournal of the Neurological Sciences [0022510X]. 333, 2013.
Hauser, Robert A|Hsu, Ann|Kell, Sherron|Espay, Alberto J|Sethi, Kapil|Stacy, Mark|Ondo, William|O'Connell, Martin|Gupta, Suneel Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trialLancet Neurology [14744422]. 12(4) , 2013.
Fernandez, Hubert H.|Vanagunas, Arvydas|Odin, Per|Espay, Alberto J.|Hauser, Robert A.|Standaert, David G.|Chatamra, Krai|Benesh, Janet|Pritchett, Yili|Hass, Steven L.|Lenz, Robert A. Levodopa–carbidopa intestinal gel in advanced Parkinson's disease open-label study: Interim resultsParkinsonism and Related Disorders [13538020]. 19(3) , 2013.
Pourcher, Emmanuelle|Factor, Stewart A.|Togasaki, Daniel M.|Hauser, Robert A.|Wolski, Kenneth|Huyck, Susan|Cantillon, Marc|Ho, T.W. Long‐term safety and efficacy of preladenant in subjects with fluctuating Parkinson's diseaseMovement Disorders [08853185]. 28(6) , 2013.
Schapira, A. H. V.|Barone, P.|Hauser, R. A.|Mizuno, Y.|Rascol, O.|Busse, M.|Debieuvre, C.|Fraessdorf, M.|Poewe, W. Patient‐reported convenience of once‐daily versus three‐times‐daily dosing during long‐term studies of pramipexole in early and advanced Parkinson’s diseaseEuropean Journal of Neurology [13515101]. 20(1) , 2013.
Hauser, Robert A PROUD stands tall: delayed-start studies in Parkinson's diseaseLancet Neurology [14744422]. 12(8) , 2013.
Edwards, Jerri D.|Hauser, Robert A.|O'Connor, Melissa L.|Valdés, Elise G.|Zesiewicz, Theresa A.|Uc, Ergun Y. Randomized trial of cognitive speed of processing training in Parkinson diseaseNeurology [00283878]. 81(15) , 2013.
Bajaj, N.|Grachev, I.D.|Seibyl, J.|Marek, K.|Kupsch, A.|Plotkin, M.|Hauser, R.A. Sensitivity, specificity, positive and negative predictive values and accuracy of datscan™/INS; for prediction of clinical diagnosis of early parkinsonian syndromesJournal of the Neurological Sciences [0022510X]. 333, 2013.
Cisbani, Giulia|Freeman, Thomas B.|Soulet, Denis|Saint-Pierre, Martine|Gagnon, Dave|Parent, Martin|Hauser, Robert A.|Barker, Roger A.|Cicchetti, Francesca Striatal allografts in patients with Huntington’s disease: impact of diminished astrocytes and vascularization on graft viabilityBrain [00068950]. 136(2) , 2013.
Poewe, W.|Hauser, R. A.|Barone, P.|Mizuno, Y.|Debieuvre, C.|Busse, M.|Fraessdorf, M.|Rascol, O.|Schapira, A. H. V. Success rate, efficacy, and safety/tolerability of overnight switching from immediate‐ to extended‐release pramipexole in advanced Parkinson's diseaseEuropean Journal of Neurology [13515101]. 20(1) , 2013.
Rascol, Olivier|Nicholas, Anthony P.|Jaglin, Jean A.|Ge, Song|Goetz, Christopher G.|Stebbins, Glenn T.|Stacy, Mark A.|Chung, Kathryn A.|Nutt, John G.|Seppi, Klaus|Poewe, Werner|Tanner, Caroline M.|Urkowitz, Alison|Miyasaki, Janis M.|Hauser, Robert A. Which dyskinesia scale best detects treatment response?Movement Disorders [08853185]. 28(3) , 2013.
Hauser RA, Grosset DG. [123I]FP-CIT (DaTscan) SPECT brain imaging in patients with suspected parkinsonian syndromes.Journal of neuroimaging : official journal of the American Society of Neuroimaging. 22(3) : 225-30, 2012.
Lewitt PA, Hauser RA, Lu M, Nicholas AP, Weiner W, Coppard N, Leinonen M, Savola JM. Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study).Neurology. 79(2) : 163-9, 2012.
Hauser RA, Lyons KE, Pahwa R. The UPDRS-8: a brief clinical assessment scale for Parkinson''s disease.The International journal of neuroscience. 122(7) : 333-7, 2012.
Rascol O, Bronzova J, Hauser RA, Lang AE, Sampaio C, Theeuwes A, van de Witte SV. Pardoprunox as adjunct therapy to levodopa in patients with Parkinson''s disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial.Parkinsonism & related disorders. 18(4) : 370-6, 2012.
Hauser RA. IPX066: a novel carbidopa-levodopa extended-release formulation.Expert review of neurotherapeutics. 12(2) : 133-40, 2012.
Goldman SM, Kamel F, Ross GW, Jewell SA, Bhudhikanok GS, Umbach D, Marras C, Hauser RA, Jankovic J, Factor SA, Bressman S, Lyons KE, Meng C, Korell M, Roucoux DF, Hoppin JA, Sandler DP, Langston JW, Tanner CM. Head injury, α-synuclein Rep1, and Parkinson''s disease.Annals of neurology. 71(1) : 40-8, 2012.
Hauser, Robert A.|Grosset, Donald G. [ 123 I]FP‐CIT (DaTscan) SPECT Brain Imaging in Patients with Suspected Parkinsonian SyndromesJournal of Neuroimaging [10512284]. 22(3) , 2012.
Schapira, A.|Barone, P.|Hauser, R.|Mizuno, Y.|Rascol, O.|Busse, M.|Debieuvre, C.|Fraessdorf, M.|Poewe, W. 2.263 PATIENT-REPORTED CONVENIENCE OF ONCE-DAILY VS TID DOSING DURING LONG-TERM STUDIES OF PRAMIPEXOLE IN EARLY AND ADVANCED PARKINSON'S DISEASEParkinsonism and Related Disorders [13538020]. 18, 2012.
Poewe, W.|Barone, P.|Hauser, R.|Mizuno, Y.|Rascol, O.|Busse, M.|Debieuvre, C.|Fraessdorf, M.|Schapira, A. 2.265 LONG-TERM SAFETY AND SUSTAINED EFFICACY OF EXTENDED-RELEASE PRAMIPEXOLE IN EARLY AND ADVANCED PARKINSON'S DISEASEParkinsonism and Related Disorders [13538020]. 18, 2012.
Morelli, Micaela|Blandini, Fabio|Simola, Nicola|Hauser, Robert A. A 2A Receptor Antagonism and Dyskinesia in Parkinson’s DiseaseParkinson's Disease [20908083]. 2012, 2012.
Morelli M, Blandini F, Simola N, Hauser RA. A(2A) Receptor Antagonism and Dyskinesia in Parkinson''s Disease.Parkinson''s disease. 2012: 489853, 2012.
Jung Kang, Un|Auinger, Peggy|Marek, Kenneth|Seibyl, John|Russell, David S.|Jennings, Danna|Fussell, Barbara|Shinaman, Aileen|Shoulson, Ira|Kieburtz, Karl|Ramos, Serrano|Simuni, Tanya|Siderowf, Andrew|Colcher, Amy|Lloyd, Mary|Trugman, Joel|Wooten, G. Frederick|Rost-Ruffner, Elke|Waters, Cheryl|Lew, Mark|Welsh, Mickie|Kawai, Connie|Kurlan, Roger|Richard, Irene|Pearson, Nancy|Zhao, Hongwei|Oakes, David|Schifitto, Giovanni|Suchowersky, Oksana|Ranawaya, Ranjit|Wood, Susan|Pantella, Carol|Pahwa, Rajesh|Dubinsky, Richard M.|Martin, Wayne|Roberts, Ted|King, Pamela|Weiner, William|Shulman, Lisa|Koller, William|Lyons, Kelly|Albin, Roger|Frey, Kirk|Wernette, Kristine|Rudolph, Alice|Hauser, Robert|Zesiewicz, Theresa|Gauger, Lisa|Mark, Margery H.|Sage, Jacob I.|Caputo, Debbie|Perlmutter, Joel|Racette, Brad A.|O'Brien, Christopher|Kumar, Rajeev|Seeberger, Lauren|Judd, Deborah|Samanta, Johan|Stacy, Mark|Williamson, Kelli|Harrigan, Mary|Feldman, Robert G.|Brown, Diane|Jankovic, Joseph|Ondo, William|Atassi, Farah|Hunter, Christine|Factor, Stewart A.|Molho, Eric|Evans, Sharon|Juncos, Jorge|Watts, Ray|Partlow, Anna|Olanow, C. Warren|Brin, Mitchell|Danisi, Fabio|Benabou, Reina|Gould, Harry|Rao, Jayaraman|McKendrick, Ann|Caviness, John N.|Adler, Charles|Lind, Marlene|Dawson, Ted|Reich, Stephen|Dunlop, Rebecca|Wszolek, Zbigniew|Uitti, Ryan|Turk, Margaret|Standaert, David|Schwarzschild, Michael A.|Growdon, John H.|Tennis, Marsha|Panisset, Michel|Hall, Jean|Gauthier, Serge|Gancher, Stephen|Hammerstad, John P.|Stone, Claudia|Alexander-Brown, Barbara|Hubble, Jean|Paulson, George W.|Reider, Carson|Truong, Daniel D.|Pathak, Mayank|Tuite, Paul|Rottenberg, David|Hansen, Joy|Barclay, C. Lynn|Grimes, David A.|Sutherland, Laura|Mendis, Tilak|Reyes, Lydia|Greene, Paul|Ford, Blair|Moskowitz, Carol|Fahn, Stanley|Jacques, Carol|Friedman, Joseph H.|Lannon, Margaret|Saint-Hilaire, Marie H.|Ellias, Samuel|Thomas, Cathi-Ann|Clark, Jeffrey|Manyam, Bala|Simpson, Patricia|Wulbrecht, Brian|Whetteckey, Jacqueline|Comella, Cynthia L.|Goetz, Christopher|Blasucci, Lucia M.|Tanner, Caroline|Tetrud, James|Togasaki, Daniel M.|Stewart, Tracy|Lang, Anthony|Birnbaum, Alex|Miyasaki, Janis|Johnston, Lisa|So, Julie Activity enhances dopaminergic long-duration response in Parkinson diseaseNeurology [00283878]. 78(15) , 2012.
Elm JJ; The NINDS NET-PD Investigators. Design innovations and baseline findings in a long-term Parkinson’s trial: The national institute of neurological disorders and stroke exploratory trials in Parkinson’s Disease Long-Term Study-1Mov Disord. 12(27) : 1513-1521, 2012.
Mizuno, Yoshikuni|Yamamoto, Mitsutoshi|Kuno, Sadako|Hasegawa, Kazuko|Hattori, Nobutaka|Kagimura, Tatsuro|Sarashina, Akiko|Rascol, Olivier|Schapira, Anthony H.V.|Barone, Paolo|Hauser, Robert A.|Poewe, Werner Efficacy and Safety of Extended- Versus Immediate-Release Pramipexole in Japanese Patients With Advanced and L-dopa–Undertreated Parkinson Disease: A Double-Blind, Randomized TrialClinical Neuropharmacology [03625664]. 35(4) , 2012.
Mizuno Y, Yamamoto M, Kuno S, Hasegawa K, Hattori N, Kagimura T, Sarashina A, Rascol O, Schapira AH, Barone P, Hauser RA, Poewe W. Efficacy and safety of extended- versus immediate-release pramipexole in Japanese patients with advanced and L-dopa-undertreated Parkinson disease: a double-blind, randomized trial.Clinical neuropharmacology. 35(4) : 174-81, 2012.
Charles, David|Brashear, Allison|Hauser, Robert A.|Li, Hung-Ir|Boo, Lee-Ming|Brin, Mitchell F. Efficacy, Tolerability, and Immunogenicity of OnabotulinumtoxinA in a Randomized, Double-Blind, Placebo-Controlled Trial for Cervical DystoniaClinical Neuropharmacology [03625664]. 35(5) , 2012.
Charles D, Brashear A, Hauser RA, Li HI, Boo LM, Brin MF. Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia.Clinical Neuropharmacology. 35(5) : 208-14, 2012.
Goldman, Samuel M.|Kamel, Freya|Ross, G. Webster|Jewell, Sarah A.|Bhudhikanok, Grace S.|Umbach, David|Marras, Connie|Hauser, Robert A.|Jankovic, Joseph|Factor, Stewart A.|Bressman, Susan|Lyons, Kelly E.|Meng, Cheryl|Korell, Monica|Roucoux, Diana F.|Hoppin, Jane A.|Sandler, Dale P.|Langston, J. William|Tanner, Caroline M. Head injury, alpha‐synuclein Rep1, and Parkinson's diseaseAnnals of Neurology. 71(1) , 2012.
Hauser, Robert A IPX066: a novel carbidopa–levodopa extended-release formulationExpert Review of Neurotherapeutics. 12(2) , 2012.
Rascol, O.|Bronzova, J.|Hauser, R.A.|Lang, A.E.|Sampaio, C.|Theeuwes, A.|van de Witte, S.V. Pardoprunox as adjunct therapy to levodopa in patients with Parkinson’s disease experiencing motor fluctuations: Results of a double-blind, randomized, placebo-controlled, trialParkinsonism and Related Disorders [13538020]. 18(4) , 2012.
LeWitt, Peter A.|Hauser, Robert A.|Lu, Mei|Nicholas, Anthony P.|Weiner, William|Coppard, Nicholas|Leinonen, Mika|Savola, Juha-Matti Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)Neurology [00283878]. 79(2) , 2012.
Hauser, R.|Nausieda, P.|Surmann, E.|Moran, K.|Barone, P. Rotigotine Transdermal System Improves Neuropsychiatric Features (Apathy, Anhedonia, Anxiety, and Depression) and Fatigue in Patients with Parkinson's Disease: A Post-Hoc Analysis of Five Double-Blind Placebo-Controlled Studies (P06.088)Neurology [00283878]. 78(Meeting Abstract) , 2012.
Hauser, Robert A.|Lyons, Kelly E.|Pahwa, Rajesh The UPDRS-8: A Brief Clinical Assessment Scale for Parkinson's DiseaseInternational Journal of Neuroscience. 122(7) , 2012.
Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, Salin L, Juhel N, Poewe W. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial.Neurology. 77(8) : 767-74, 2011.
Hauser RA, Cantillon M, Pourcher E, Micheli F, Mok V, Onofrj M, Huyck S, Wolski K. Preladenant in patients with Parkinson''s disease and motor fluctuations: a phase 2, double-blind, randomised trial.Lancet neurology. 10(3) : 221-9, 2011.
Rascol, Olivier|Fitzer-Attas, Cheryl J|Hauser, Robert|Jankovic, Joseph|Lang, Anthony|Langston, J William|Melamed, Eldad|Poewe, Werner|Stocchi, Fabrizio|Tolosa, Eduardo|Eyal, Eli|Weiss, Yoni M|Olanow, C Warren A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomesLancet Neurology [14744422]. 10(5) , 2011.
Rascol, O., Fitzer-Attas, C.J., Hauser, R., Jankovic, J., Lang, A., Langston, J. W., …& Olanow, C. W. A double-blind, delayed-start trial of rasgiline in Parkinson’s disease (the ADAGIO study) : prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.The Lancet Neurology. 5(10) : 415-423, 2011.
Friedman JH, Agarwal P, Alcalay R, Black KJ, Chou KL, Cote L, Dayalu P, Frank S, Hartlein J, Hauser RA, Lang AE, Marsh L, Marshall F, Moskowitz C, Ravina B, Riley D, Sanchez-Ramos J, Simon DK, Simuni T, Sutton J, Tuite P, Weintraub D, Zesiewicz T. Clinical vignettes in Parkinson''s disease: a collection of unusual medication-induced hallucinations, delusions, and compulsive behaviours.Int J Neurosci.. 8(121) : 767-74, 2011.
Hsu, Ann|O'Connell, Martin J.|Modi, Nishit B.|Yao, Hsuan‐Ming|Kell, Sherron H.|Gupta, Suneel K.|Hauser, Robert A.|Ellenbogen, Aaron L.|Metman, Leo Verhagen Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's diseaseMovement Disorders. 26(12) , 2011.
Hauser RA, Ellenbogen AL, Metman LV, Hsu A, O''Connell MJ, Modi NB, Yao HM, Kell SH, Gupta SK. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson''s diseaseMov Disord. 12(26) : 2246-52, 2011.
Hauser, Robert A.|Auinger, Peggy Determination of minimal clinically important change in early and advanced Parkinson's diseaseMovement Disorders. 26(5) , 2011.
Hauser RA, Auinger P, Parkinson Study Group. Determination of Minimal Clinically Important Change in Early and Advanced Parkinson''s Disease.Mov Disord. 5(26) : 813-8., 2011.
Schapira, A.H.V.|Barone, P.|Hauser, R.A.|Mizuno, Y.|Rascol, O.|Busse, M.|Salin, L.|Juhel, N.|Poewe, W. Extended-release pramipexole in advanced Parkinson disease: A randomized controlled trialNeurology. 77(8) , 2011.
Poewe, W.|Rascol, O.|Barone, P.|Hauser, R.A.|Mizuno, Y.|Haaksma, M.|Salin, L.|Juhel, N.|Schapira, A.H.V. Extended-release pramipexole in early Parkinson disease: A 33-week randomized controlled trialNeurology. 77(8) : 759-66, 2011.
Hauser RA. Future treatments for Parkinson’s disease: surfing the PD pipelineInt J Neurosci.. 2(121) : 53-62, 2011.
Hauser, Robert A. Future Treatments for Parkinson's Disease: Surfing the PD PipelineInternational Journal of Neuroscience. 121(sup2) , 2011.
Gross RE, Watts RL, Hauser RA, Bakay RA, Reichmann H, von Kummer R, Ondo WG, Reissig E, Eisner W, Steiner-Schulze H, Siedentop H, Fichte K, Hong W, Cornfeldt M, Beebe K, Sandbrink R; the Spheramine Investigational Group. Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson''s disease: a double-blind, randomised, controlled trialLancet Neurol. 6(10) : 509-519, 2011.
Gross, Robert E|Watts, Raymond L|Hauser, Robert A|Bakay, Roy AE|Reichmann, Heinz|von Kummer, Rüdiger|Ondo, William G|Reissig, Elke|Eisner, Wilhelm|Steiner-Schulze, Heike|Siedentop, Harald|Fichte, Klaus|Hong, Walter|Cornfeldt, Michael|Beebe, Katherine|Sandbrink, Rupert Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trialLancet Neurology [14744422]. 10(6) , 2011.
Hauser, Robert A.|Reichmann, Heinz|Lew, Mark|Asgharian, Afsaneh|Makumi, Clare|Shulman, Kenneth J. Long-term, Open-label Study of Once-daily Ropinirole Prolonged Release in Early Parkinson's DiseaseInternational Journal of Neuroscience. 121(5) , 2011.
Hauser RA, Reichmann H, Lew M, Asgharian A, Makumi C, Shulman KJ. Long-term, Open-label Study of Once-daily Ropinirole Prolonged Release in Early Parkinson''s Disease.Int J Neurosci. 5(121) : 246-53, 2011.
Sampaio, Cristina|Bronzova, Juliana|Hauser, Robert A.|Lang, Anthony E.|Rascol, Olivier|van de Witte, Serge V.|Theeuwes, and Ad Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trialsMovement Disorders. 26(8) , 2011.
Sampaio C, Bronzova J, Hauser RA, Lang AE, Rascol O, van de Witte SV, Theeuwes AA; for the Rembrandt/Vermeer Study Groups. Pardoprunox in early Parkinson''s disease: Results from 2 large, randomized double-blind trials.Mov Disord. 8(26) : 1464-76, 2011.
Hauser, Robert A|Cantillon, Marc|Pourcher, Emmanuelle|Micheli, Federico|Mok, Vincent|Onofrj, Marco|Huyck, Susan|Wolski, Kenneth Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trialLancet Neurology. 10(3) , 2011.
Elmer, Lawrence|Hauser, Robert A Strategies for Parkinson’s disease care: prevention and management of motor fluctuationsNeurodegenerative Disease Management [17582024]. 1(5) , 2011.
Antonini, Angelo|Martinez‐Martin, Pablo|Chaudhuri, Ray K.|Merello, Marcelo|Hauser, Robert|Katzenschlager, Regina|Odin, Per|Stacy, Mark|Stocchi, Fabrizio|Poewe, Werner|Rascol, Oliver|Sampaio, Cristina|Schrag, Anette|Stebbins, Glenn T.|Goetz, Christopher G. Wearing‐off scales in Parkinson's disease: Critique and recommendationsMovement Disorders. 26(12) , 2011.
Hauser RA, Schapira AH, Rascol O, Barone P, Mizuno Y, Salin L, Haaksma M, Juhel N, Poewe W. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson''s disease.Movement Disorders : Official Journal of the Movement Disorder Society. 25(15) : 2542-9, 2010.
Rascol O, Barone P, Hauser RA, Mizuno Y, Poewe W, Schapira AH, Salin L, Sohr M, Debieuvre C. Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson''s disease.Movement Disorders : Official Journal of the Movement Disorder Society. 25(14) : 2326-32, 2010.
Colosimo C, Martínez-Martín P, Fabbrini G, Hauser RA, Merello M, Miyasaki J, Poewe W, Sampaio C, Rascol O, Stebbins GT, Schrag A, Goetz CG. Task force report on scales to assess dyskinesia in Parkinson''s disease: critique and recommendations.Movement Disorders : Official Journal of the Movement Disorder Society. 25(9) : 1131-42, 2010.
Lew MF, Hauser RA, Hurtig HI, Ondo WG, Wojcieszek J, Goren T, Fitzer-Attas CJ. Long-term efficacy of rasagiline in early Parkinson''s disease.The International Journal of neuroscience. 120(6) : 404-8, 2010.
Hersh BP, Earl NL, Hauser RA, Stacy M. Early treatment benefits of ropinirole prolonged release in Parkinson''s disease patients with motor fluctuations.Movement Disorders : Official Journal of the Movement Disorder Society. 25(7) : 927-31, 2010.
Watts RL, Lyons KE, Pahwa R, Sethi K, Stern M, Hauser RA, Olanow W, Gray AM, Adams B, Earl NL. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson''s disease.Movement Disorders : Official Journal of the Movement Disorder Society. 25(7) : 858-66, 2010.
Bronzova J, Sampaio C, Hauser RA, Lang AE, Rascol O, Theeuwes A, van de Witte SV, van Scharrenburg G. Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson''s disease.Movement Disorders : Official Journal of the Movement Disorder Society. 25(6) : 730-8, 2010.
Hauser RA. Early pharmacologic treatment in Parkinson''s disease.The American Journal of Managed Care. 16: S100-7, 2010.
Bronzova, Juliana|Sampaio, Cristina|Hauser, Robert A.|Lang, Anthony E.|Rascol, Olivier|Theeuwes, Ad|van de Witte, Serge V.|van Scharrenburg, Guus Double‐blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's diseaseMovement Disorders. 25(6) , 2010.
Hersh, Bonnie P.|Earl, Nancy L.|Hauser, Robert A.|Stacy, Mark Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuationsMovement Disorders. 25(7) , 2010.
Rascol, Olivier|Barone, Paolo|Hauser, Robert A.|Mizuno, Yoshikuni|Poewe, Werner|Schapira, Anthony H.V.|Salin, Laurence|Sohr, Mandy|Debieuvre, Catherine Efficacy, safety, and tolerability of overnight switching from immediate‐ to once daily extended‐release pramipexole in early Parkinson's diseaseMovement Disorders. 25(14) , 2010.
Lew, Mark F.|Hauser, Robert A.|Hurtig, Howard I.|Ondo, William G.|Wojcieszek, Joanne|Goren, Tamar|Fitzer-Attas, Cheryl J. Long-Term Efficacy of Rasagiline in Early Parkinson's DiseaseInternational Journal of Neuroscience. 120(6) , 2010.
Watts, Ray L.|Lyons, Kelly E.|Pahwa, Rajesh|Sethi, Kapil|Stern, Matthew|Hauser, Robert A.|Olanow, Warren|Gray, Alex M.|Adams, Bryan|Earl, Nancy L. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's diseaseMovement Disorders. 25(7) , 2010.
Lyons, Kelly E.|Friedman, Joseph H.|Hermanowicz, Neal|Isaacson, Stuart H.|Hauser, Robert A.|Hersh, Bonnie P.|Silver, Dee E.|Tetrud, James W.|Elmer, Lawrence W.|Parashos, Sotirios A.|Struck, Lynn K.|Lew, Mark F.|Pahwa, Rajesh Orally Disintegrating Selegiline in Parkinson Patients With Dopamine Agonist-Related Adverse EffectsClinical Neuropharmacology. 33(1) , 2010.
Lyons KE, Friedman JH, Hermanowicz N, Isaacson SH, Hauser RA, Hersh BP, Silver DE, Tetrud JW, Elmer LW, Parashos SA, Struck LK, Lew MF, Pahwa R. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects.Clinical Neuropharmacology. 33(1) : 5-10, 2010.
Hauser, Robert A.|Schapira, Anthony H.V.|Rascol, Olivier|Barone, Paolo|Mizuno, Yoshikuni|Salin, Laurence|Haaksma, Monika|Juhel, Nolwenn|Poewe, Werner Randomized, double‐blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's diseaseMovement Disorders. 25(15) , 2010.
Hauser, Robert A.|Lyons, Kelly E. Reply: Intravenous glutathione in Parkinson's diseaseMovement Disorders. 25(7) , 2010.
Colosimo, Carlo|Martínez‐Martín, Pablo|Fabbrini, Giovanni|Hauser, Robert A.|Merello, Marcelo|Miyasaki, Janis|Poewe, Werner|Sampaio, Cristina|Rascol, Olivier|Stebbins, Glenn T.|Schrag, Anette|Goetz, Christopher G. Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendationsMovement Disorders. 25(9) , 2010.
Butterfield, London C.|Cimino, Cynthia R.|Oelke, Lynn E.|Hauser, Robert A.|Sanchez-Ramos, Juan The independent influence of apathy and depression on cognitive functioning in Parkinson's disease.Neuropsychology. 24(6) , 2010.
Butterfield LC, Cimino CR, Oelke LE, Hauser RA, Sanchez-Ramos J. The independent influence of apathy and depression on cognitive functioning in Parkinson''s disease.Neuropsychology. 6(24) : 721-30, 2010.
Hauser RA, Auinger P, Oakes D. Levodopa response in early Parkinson''s disease.Movement Disorders : Official Journal of the Movement Disorder Society. 24(16) : 2328-36, 2009.
Hauser RA. New considerations in the medical management of early Parkinson''s disease: impact of recent clinical trials on treatment strategy.Parkinsonism & Related Disorders. 15: S17-21, 2009.
Isaacson SH, Hauser RA. Improving symptom control in early Parkinson''s disease.Therapeutic advances in neurological disorders. 2(6) : 29-41, 2009.
Tanner CM, Ross GW, Jewell SA, Hauser RA, Jankovic J, Factor SA, Bressman S, Deligtisch A, Marras C, Lyons KE, Bhudhikanok GS, Roucoux DF, Meng C, Abbott RD, Langston JW. Occupation and risk of parkinsonism: a multicenter case-control study.Archives of Neurology. 66(9) : 1106-13, 2009.
Seeberger LC, Hauser RA. Levodopa/carbidopa/entacapone in Parkinson''s disease.Expert Review of Neurotherapeutics. 9(7) : 929-40, 2009.
Cicchetti F, Saporta S, Hauser RA, Parent M, Saint-Pierre M, Sanberg PR, Li XJ, Parker JR, Chu Y, Mufson EJ, Kordower JH, Freeman TB. Neural transplants in patients with Huntington''s disease undergo disease-like neuronal degeneration.Proceedings of the National Academy of Sciences of the United States of America. 106(30) : 12483-8, 2009.
Connors JJ, Sacks D, Furlan AJ, Selman WR, Russell EJ, Stieg PE, Hadley MN, Wojak JC, Koroshetz WJ, Heros RC, Strother CM, Duckwiler GR, Durham JD, Tom-sick TO, Rosenwasser RH, McDougall CG, Haughton VM, Derdeyn CP, Wechsler LR, Hudgins PA, Alberts MJ, Raabe RD, Gomez CR, Cawley CM, Krol KL, Futrell N, Hauser RA, Frank JI. Training, competency, and credentialing standards for diagnostic cervicocerebral angiography, carotid stenting, and cerebrovascular intervention: a joint statement from the American Academy of Neurology, the American Association of Neurological Surgeons, the American Society of Interventional and Therapeutic Neuroradiology, the American Society of Neuroradiology, the Congress of Neurological Surgeons, the AANS/CNS Cerebrovascular Section, and the Society of Interventional Radiology.Journal of vascular and interventional radiology : JVIR. 20(7 Suppl) : S292-301, 2009.
Hauser RA, Lyons KE, McClain T, Carter S, Perlmutter D. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson''s disease.Movement disorders : official journal of the Movement Disorder Society. 24(7) : 979-83, 2009.
Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson''s disease.Movement Disorders : Official Journal of the Movement Disorder Society. 24(4) : 541-50, 2009.
Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson''s disease.Movement disorders : official journal of the Movement Disorder Society. 24(4) : 564-73, 2009.
Olanow, C. Warren|Rascol, Olivier|Hauser, Robert|Feigin, Paul D.|Jankovic, Joseph|Lang, Anthony|Langston, William|Melamed, Eldad|Poewe, Werner|Stocchi, Fabrizio|Tolosa, Eduardo A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's DiseaseNew England Journal of Medicine. 361(13) , 2009.
Snyder, Evan Y.|Acosta, S. A.|Jernberg, J.|Cole, M.|Schlunk, A.|Shytle, R. D.|Tan, J.|Sanberg, C.|Sanberg, P.|Gemma, G.|Bickford, P. C.|Airavaara, M.|Harvey, B.|Chiocco, M.|Howard, D.|Peränen, J.|Saarma, M.|Wang, Y.|Hoffer, B.|Andres, R. H.|Pendharkar, A. V.|Guzman, R.|De, A.|Bliss, T. M.|McMillan, E.|Svendsen, C. N.|Gambhir, S. S.|Widmer, H. R.|Wallimann, T.|Steinberg, G. K.|Bachstetter, A. D.|Jernberg, J.|Schlunk, A.|Hudson, C. E.|Bickford, P. C.|Gemma, C.|Baek, S.-H.|Kim, E.-K.|Lee, H.|Park, S. K.|Lookingland, K. J.|Goudreau, J. L.|Kim, S. W.|Yu, and S.-W.|Behrouz, B.|Lookingland, K.|Goudreau, J.|Berk, M. A.|Salli, U.|Ramachandra, R.|Venkiteswaran, K.|Subramanian, and T.|Bernal, G. M.|Peterson, D. A.|Bjugstad, K. B.|Lampe, K.|Kern, D. S.|Mahoney, M.|Bobek, V.|Kolostova, K.|Pinterova, D.|Boubelik, M.|Raska, O.|Rokyta, R.|Jirkovska, M.|Boger, H. A.|Middaugh, L. D.|Granholm, A.-Ch.|Chermenina, M.|Nevalainen, N.|Marschinke, F.|Rehnmark, A.|Berglöf, E.|Strömberg, I.|Cicchetti, F.|Saporta, S.|Hauser, R. A.|Parent, M.|Saint-Pierre, M.|Sanberg, P. R.|Li, X. J.|Parker, J. R.|Chu, Y.|Mufson, E. J.|Kordower, J. H.|Freeman, T. B.|Collado, L. M.|Collado, M. E.|Hama, A.|Gajavelli, S.|Sagen, J.|Daadi, M. M.|Arac, A.|Li, Z.|Sun, G.|Wu, J. C.|Steinberg, G. K.|Dodiya, H. B.|Kirik, D.|Mandel, R.|Stansell, III, J.|Björklund, A.|Kordower, J. H.|Emborg, E. M.|Johnson, J.|Swanson, C.|Dobbert, M.|Joers, V.|Brunner, K.|Kemnitz, J.|Ziegler, T.|Eve, D. J.|Musso, III, J.|Park, D.-H.|Bui, V.|Smith, A.|Cameron, D.|Oliveira, C.|Pollock, K.|Hope, A.|Baradez, M.-O.|Sinden, J. D.|Sanberg, P. R.|Federici, T.|Raore, B.|Taub, J.|Johe, K.|Boulis, N.|Fortress, A. M.|Helke, K. L.|Granholm, L.|Freeman, L.|Granholm, A.-Ch.|Garbuzova-Davis, S.|Xie, Y.|Zayko, O.|Sanberg, and P. R.|Ghosh, M.|Tuesta, L. M.|Puentes, R.|Monaco, B.|El Maarouf, A.|Rutishauser, U.|Pearse, D. D.|Golshani, R.|Savant-Bhonsale, S.|Tuesta, L. M.|Louro, J.|Wilson, T.|Patel, S.|Pearse, D. D.|Gombash, S. E.|Cole-Strauss, A.|Lipton, J. W.|Collier, T. J.|Steece-Collier, K.|Terpstra, B. T.|Spieles-Engemann, A. L.|Daley, B. F.|Wohlgenant, S. L.|Thompson, V. B.|Mandel, R. J.|Manfredsson, F.|Sortwell, C. E.|Gorenkova, N.|Franco, C.|Hassani, Z.|Price, J.|West, J.|Modo, M.|Granholm, A.-Ch.|Fortress, A.|Lockrow, J.|Moore, A.|Williams, B.|Helke, K.|Buhusil, M.|Hallett, P. J.|Vinuela, A.|Licznerski, P.|Sotnikova, T. D.|Caron, M. G.|Gainetdinov, R. R.|Isacson, O.|Harvey, B. K.|Chou, J.|Shen, H.|Chiang, Y. H.|Hoffer, B. J.|Wang, Y.|Hayashi, T.|Kaneko, Y.|Yu, S. J.|Parolini, O.|Borlongan, C. V.|Hess, D. C.|Deans, R. J.|Mays, R. W.|Jain, A.|Henao, H.|Puentes, R.|Bleicher, D.|Maggio, D.|Pearse, and D. D.|Jensen, P.|Meyer, M.|Ducray, A. D.|Widmer, H. R.|Jergova, S.|Collado, L.|Collado, M.|Varghese, M.|Furmanski, O.|Hama, A.|Gajavelli, S.|Sagen, J.|Jinwal, U. K.|Miyata, Y.|Koren, III, J.|Jones, J. R.|Trotter, J. H.|Chang, L.|O'Leary, L.|Morgan, D.|Lee, D. C.|Shults, C. L.|Rousaki, A.|Weeber, E. J.|Zuiderweg, E. R. P.|Gestwicki, J. E.|Dickey, C. A.|Johansson, S.|Vernon, A. C.|Price, J.|Modo, M.|Kelly, L.|Newman, M.|Smith, A.|Bakay, R.|Khaing, Z. Z.|Seidlits, S. K.|Rosenberger, R. R.|Vanscoy, J. E.|Schmidt, C. E.|Khaing, Z. Z.|Vanscoy, J. E.|Seidlits, S. K.|Grill, R. J.|Schmidt, C. E.|Kuruba, R.|Hattiangady, B.|Shuai, B.|Shetty, A. K.|Lee, C.-T.|Chen, J.|Errico, S.|Worden, L. T.|Amable, R.|Freed, W. J.|Lee, D. C.|Lebson, L.|Rizer, J.|Ruiz, C.|Rojiani, R.|Gordon, M. N.|Morgan, D.|Lieu, C. A.|Marupudi, N. I.|Berk, M. A.|Ramachandra, R.|Subramanian, T.|Li, Q.|Gordon, M. N.|Chackerian, B.|Alamed, J.|Ugen, K. E.|Morgan, D.|Luo, Y.|Kuo, C.-C.|Shen, H.|Chou, J.|Greig, N. H.|Hoffer, B. J.|Wang, Y.|Ma, B.-F.|Xue, Y.-Q.|Zhao, L.-R.|Duan, W.-M.|Macklis, J. D.|Madhavan, L.|Daley, B. F.|Paumier, K. L.|Collier, T. J.|Maksoud, Y. A.|Manfredsson, F. P.|Rising, A.|Burger, C.|Hasona, K.|Muzyczka, N.|Mandel, R. J.|Manfredsson, F. P.|Tumer, N.|Erdos, B.|Landa, T.|Broxson, C. S.|Sullivan, L. F.|Rising, A. C.|Foust, K. D.|Zhang, Y.|Muzyczka, N.|Gorbatyuk, O. S.|Scarpace, P. J.|Mandel, R. J.|Marschinke, F.|Oldenborg, P.-A.|Strömberg, I.|Marupudi, N. I.|Lieu, C.|Tombran-Tink, J.|Ramachandra, R.|Subramanian, T.|Mervis, R. F.|Kotick, J.|Shah, M.|Winkler, A.|Kasimos, K.|Joshi, S.|Scheff, S.|Mufson, E. J.|Miller, C.|Sanberg, P. R.|Kuzmin-Nichols, N.|Sanberg, C. D.|Garbuzova-Davis, S.|Monahan, A. J.|Ling, Z.|Carvey, P. M.|Moradian, S.|Pick, C. G.|Rubovitch, V.|Kaminsky, J.|Mervis, R. F.|Musso, III, J.|Eve, D. J.|Park, D.-H.|Oliveria, C.|Pollick, K.|Hope, A.|Baradez, M.-O.|Sinden, J. D.|Sanberg, P. R.|Neckel, N. D.|Nevalainen, N.|af Bjerkén, S.|Gerhardt, G.|Strömberg, I.|Newman, M. B.|Smith, A. P.|Kelly, L. P.|Bakay, R. A. E.|Nguyen, T.|Hupalo, N.|Jimenez, J.|Morgan, D.|Alcantar, N.|Nikas, J. B.|Low, W. C.|Pabn, M. M.|Hudson, C. E.|Jernberg, J.|Bachstetter, A.|Acosta, S. A.|Gemma, C.|Klein, R.|Bickford, P. C.|Parihar, V. K.|Shuai, B.|Hattiangady, B.|Kuruba, R.|Shetty, A. K.|Park, D.-H.|Eve, D. J.|Musso, III, J.|Gemma, C.|Bachstetter, A. D.|Wolfson, A.|Schlunk, A.|Baradez, M.-O.|Sinden, J. D.|Sanberg, P. R.|Pendharkar, A. V.|De, A.|Wang, H.|Gaeta, X.|Wang, N.|Andres, R. H.|Chen, X.|Gambhir, S. S.|Guzman, R.|Piao, C.-S.|Zhao, L.-R.|Priest, C.|Davies, A.|Wirth, E.|Conta, A.|Polonskaya, Y.|Polonskowski, J.|Rachubinski, A.|Cornelius, S. K.|Maclean, K. N.|Bjugstad, K. B.|Rehnmark, A.|Bickford, P. C.|Strömberg, I.|Ross, J. M.|Brené, S.|berg, J.|Sitnikov, R.|Pernold, K.|Terzioglu, M.|Trifunovic, A.|Kehr, J.|Larsson, N.-G.|Hoffer, B. J.|Olson, L.|Rossignol, J.|Boyer, C.|Lévque, X.|Dunbar, G. L.|Lescaudron, L.|Sanchez-Ramos, J.|Song, S.|Mori, T.|Patel, N.|Cao, C.|Arendash, G.|Selenica, M.-L. B.|Dickey, C.|Gordon, M.|Morgan, D.|Shahaduzzaman, S. D.|Golden, J. E.|Green, S. M.|Womble, T.|Sanberg, P. R.|Pennypacker, K. R.|Willing, A. E.|Sinden, J.|Singec, I.|Snyder, E. Y.|Sladek, Jr., J. R.|Elsworth, J. D.|Roth, R. H.|Leranth, C.|Collier, T. J.|Bjugstad, K. B.|Blanchard, B. C.|Samulski, R. J.|Aebischer, P.|Redmond, Jr., D. E.|Smith, A. J.|Shytle, R. D.|Tan, J.|Bickford, P. C.|Rezai-zadeh, K.|Hou, L.|Zeng, J.|Sanberg, P. R.|Sanberg, C. D.|Roschek, Jr., B.|Fink, R. C.|Albert, R. S.|Spieles-Engemann, A. L.|Behbehani, M. M.|Collier, T. J.|Steece-Collier, K.|Wohlgenant, S. L.|Thompson, V. B.|Lipton, J. W.|Sortwell, C. E.|Spieles-Engemann, A. M.|Behbehani, M. M.|Collier, T. J.|Wohlgenant, S. L.|Mandybur, G. T.|Lipton, J. W.|Terpstra, B. T.|Sortwell, C. E.|Steece-Collier, K.|Soderstrom, K.|O'Malley, J.|Stancati, J.|Levine, N.|Sortwell, C.|Lipton, J.|Collier, T.|Stoner, S.|Sanberg, P. R.|Garbuzova-Davis, S.|Strömberg, I.|Marscinke, F.|Nevalainen, N.|Chermenina, M.|Rehnmark, A.|Berglöf, E.|af Bjerkén, S.|Teng, Y. D.|Yu, D.|Benedict, D. E.|Wilhelmsson, U.|Pekny, and M.|Thompson, V. B.|Sortwell, C. E.|Collier, T. J.|Steece-Collier, K.|Lipton, J. W.|Timmer, M.|Winkler, C.|Klein, A.|Sauter, J.|Oertel, W.|Nikkhah, G.|Vazin, T.|Becker, K. G.|Chen, J.|Zhang, Y.|Worden, L.|Freed, W. J.|Vorobyeva, T. M.|Berchenko, O. G.|Gejko, V. V.|Storchak, E. O.|Titkova, A. M.|Kolyadko, S. P.|Wakeman, D. R.|Redmond, Jr., D. E.|Sladek, Jr., J. R.|Snyder, E. Y.|Walczak, P.|Gorelik, M.|Levy, M.|Rumpal, N.|Rifkin, R.|Muja, N.|Kim, H.|Kerr, D. A.|Bulte, J. W. M.|Wang, L.|Shi, J.|van Ginkel, F. W.|Lan, L.|Niemeyer, G.|Martin, D. R.|Snyder, E. Y.|Cox, N. R.|Womble, T. A.|Green, S. M.|Nelson, A. P.|Shahaduzzaman, M. D.|Golden, J. E.|Sanberg, P. R.|Pennypacker, K. R.|Willing, A. E.|Woods, III, R. L.|Louis, M. K.|Zesiewicz, T.|Xie, Y.|Sullivan, K. L.|Miller, A. M.|Kuzmin-Nichols, N.|Sanberg, P. R.|Garbuzova-Davis, S.|Worden, L. T.|Lee, C.-T.|Freed, W. J.|Yu, S.|Hayashi, T.|Kaneko, Y.|Bae, E.|Stahl, C. E.|Wang, Y.|Borlongan, C. V.|Zhu, Y.|Oregon, D.|Hou, H.|Luo, D.|Mori, T.|Giunta, B.|Zhao, Y.|Town, T.|Tan, J. Abstracts for the 16th Annual Meeting of the American Society for Neural Therapy and RepairCell Transplantation [09636897]. 18(2) , 2009.
Jenner, P.|Mori, A.|Hauser, R.|Morelli, M.|Fredholm, B.B.|Chen, J.F. Adenosine, adenosine A2A antagonists, and Parkinson's diseaseParkinsonism and Related Disorders. 15(6) , 2009.
Hauser, Robert A.|Panisset, Michel|Abbruzzese, Giovanni|Mancione, Linda|Dronamraju, Nalina|Kakarieka, Algirdas Double‐blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's diseaseMovement Disorders. 24(4) , 2009.
Zesiewicz, Theresa A.|Hauser, Robert A.|Freeman, Alan|Sullivan, Kelly L.|Miller, Amber M.|Halim, Tariq Fentanyl-Induced Bradykinesia and Rigidity After Deep Brain Stimulation in a Patient With Parkinson DiseaseClinical Neuropharmacology. 32(1) , 2009.
Zesiewicz TA, Hauser RA, Freeman A, Sullivan KL, Miller AM, Halim T. Fentanyl-induced bradykinesia and rigidity after deep brain stimulation in a patient with Parkinson disease.Clinical neuropharmacology. 32(1) : 48-50, 2009.
Cobb, Stephanie A.|Wider, Christian|Ross, Owen A.|Mata, Ignacio F.|Adler, Charles H.|Rajput, Alex|Rajput, Ali H.|Wu, Ruey‐Meei|Hauser, Robert|Josephs, Keith A.|Carr, Jonathan|Gwinn, Katrina|Heckman, Michael G.|Aasly, Jan O.|Lynch, Timothy|Uitti, Ryan J.|Wszolek, Zbigniew K.|Kapatos, Gregory|Farrer, Matthew J. GCH1 in early‐onset Parkinson's diseaseMovement Disorders. 24(14) , 2009.
Hauser, Robert A.|Auinger, Peggy|Oakes, David Levodopa response in early Parkinson's diseaseMovement Disorders. 24(16) , 2009.
Sethi KD, Hauser RA, Isaacson SH, McClain T. Levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo 200) in the treatment of Parkinson''s disease: a case series.Cases Journal. 2: 7134, 2009.
Sethi, Kapil D|Hauser, Robert A|Isaacson, Stuart H|McClain, Terry Levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo® 200) in the treatment of Parkinson's disease: a case seriesCases Journal [17571626]. 2(1) , 2009.
Seeberger, Lauren C|Hauser, Robert A Levodopa/carbidopa/entacapone in Parkinson’s diseaseExpert Review of Neurotherapeutics. 9(7) , 2009.
Hauser, Robert A.|Lew, Mark F.|Hurtig, Howard I.|Ondo, William G.|Wojcieszek, Joanne|Fitzer‐Attas, Cheryl J. Long‐term outcome of early versus delayed rasagiline treatment in early Parkinson's diseaseMovement Disorders. 24(4) , 2009.
Saint-Pierre, M.|Cicchetti, F.|Sanberg, P. R.|Freeman, T. B.|Parker, J. R.|Saporta, S.|Parent, M.|Mufson, E. J.|Kordower, J. H.|Chu, Y.|Li, X. J.|Hauser, R. A. Neural transplants in patients with Huntington's disease undergo disease-like neuronal degenerationProceedings of the National Academy of Sciences of the United States of America. 106(30) , 2009.
Hauser, Robert A. New considerations in the medical management of early Parkinson's disease: Impact of recent clinical trials on treatment strategyParkinsonism and Related Disorders. 15, 2009.
Hauser, R. O.076 Medical management of early Parkinson's diseaseParkinsonism and Related Disorders. 15, 2009.
Tanner, Caroline M.|Ross, G. Webster|Jewell, Sarah A.|Hauser, Robert A.|Jankovic, Joseph|Factor, Stewart A.|Bressman, Susan|Deligtisch, Amanda|Marras, Connie|Lyons, Kelly E.|Bhudhikanok, Grace S.|Roucoux, Diana F.|Meng, Cheryl|Abbott, Robert D.|Langston, J. William Occupation and Risk of Parkinsonism: A Multicenter Case-Control StudyArchives of Neurology [00039942]. 66(9) , 2009.
Cicchetti, F.|Saporta, S.|Hauser, R.|Parent, M.|Saint-Pierre, M.|Sanberg, P.|Li, X.-J.|Parker, J.|Chu, Y.|Mufson, E.|Kordower, J.|Freeman, T. P1.016 Neural transplants in patients with Huntington's disease undergo disease-speciflc neuronal degenerationParkinsonism and Related Disorders. 15, 2009.
Hauser, R.A.|Pourcher, E.|Micheli, F.|Mok, V.|Onofrj, M.|Huyck, S.B.|Wolski, K.P.|Cantillon, M. P2.101 Efflcacy and safety of preladenant, a novel A2A receptor antagonist, as a levodopa adjunct in patients with moderate-to-severe Parkinson's diseaseParkinsonism and Related Disorders. 15, 2009.
Hauser, R.A.|Gertner, J.M.|Okamoto, M.|Reed, R.F.|Sage, J.I. P2.109 Piclozotan reduces dyskinesia and OFF time in Parkinson's disease (PD) patients with L-dopa induced motor complicationsParkinsonism and Related Disorders. 15, 2009.
Hauser, R.A.|Hunter, B.|Rolfe, K.|Giorgi, L. P2.132 Long-term safety and patient preference for dose frequency in patients receiving ropinirole prolonged release in early or advanced Parkinson's diseaseParkinsonism and Related Disorders. 15, 2009.
Ellenbogen, A.|Hauser, R.|Omidvar, O.|Hsu, A.|O'Connell, M.|Kell, S.|Gupta, S. P2.136 Comparative efflcacy and safety of a novel carbidopa–levodopa product (IPX066) and Sinemet in advanced Parkinson's diseaseParkinsonism and Related Disorders. 15, 2009.
Poewe, W.|Barone, P.|Hauser, R.|Mizuno, Y.|Rascol, O.|Schapira, A.|Haaksma, M.|Juhel, N.|Salin, L. P2.153 Once-daily pramipexole extended-release (ER) demonstrated non-inferiority compared to immediate release (IR) tid dosing in early Parkinson's diseaseParkinsonism and Related Disorders. 15, 2009.
Rascol, O.|Barone, P.|Hauser, R.|Mizuno, Y.|Poewe, W.|Schapira, A.|Debieuvre, C.|Sohr, M.|Salin, L. P2.155 Simple overnight switching from immediate- to extended-release pramipexole in early Parkinson's disease at the same daily dosageParkinsonism and Related Disorders. 15, 2009.
Schapira, A.|Barone, P.|Hauser, R.|Mizuno, Y.|Poewe, W.|Rascol, O.|Busse, M.|Juhel, N.|Salin, L. P2.159 Efflcacy and safety of once-daily (qd) pramipexole extended-release for advanced Parkinson's diseaseParkinsonism and Related Disorders. 15, 2009.
Stocchi, F.|Hunter, B.|Giorgi, L.|Hauser, R.A. P2.165 Dose-related decrease in “off” time with ropinirole prolonged release in patients with advanced Parkinson's diseaseParkinsonism and Related Disorders. 15, 2009.
Hauser, Robert A.|Lyons, Kelly E.|McClain, Terry|Carter, Summer|Perlmutter, David Randomized, double‐blind, pilot evaluation of intravenous glutathione in Parkinson's diseaseMovement Disorders. 24(7) , 2009.
Isaacson, Stuart H.|Hauser, Robert A. Review: Improving symptom control in early Parkinson’s diseaseTherapeutic Advances in Neurological Disorders. 2(6) , 2009.
Hauser, R.A.|Bronzova, J.|Sampaio, C.|Lang, A.E.|Rascol, O.|Theeuwes, A.|van de Witte, S.V. Safety and Tolerability of Pardoprunox, a New Partial Dopamine Agonist, in a Randomized, Controlled Study of Patients with Advanced Parkinson’s DiseaseEuropean Neurology. 62(1) , 2009.
Hauser RA, Bronzova J, Sampaio C, Lang AE, Rascol O, Theeuwes A, van de Witte SV. Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson''s disease.European neurology. 62(1) : 40-8, 2009.
Jahan I, Hauser RA, Sullivan KL, Miller A, Zesiewicz TA. Sleep disorders in Parkinson''s disease.Neuropsychiatric Disease and treatment. 5: 535-40, 2009.
Simuni, Tanya|Lyons, Kelly E.|Pahwa, Rajesh|Hauser, Robert A.|Comella, Cynthia|Elmer, Lawrence|Weintraub, Daniel Treatment of Early Parkinson’s DiseaseEuropean Neurology. 61(4) , 2009.
Simuni T, Lyons KE, Pahwa R, Hauser RA, Comella C, Elmer L, Weintraub D. Treatment of early Parkinson''s disease. Part 1.European neurology. 61(4) : 193-205, 2009.
Simuni T, Lyons KE, Pahwa R, Hauser RA, Comella C, Elmer L, Weintraub D. Treatment of early Parkinson''s disease. Part 2.European neurology. 61(4) : 206-15, 2009.
Kordower JH, Chu Y, Hauser RA, Olanow CW, Freeman TB. Transplanted dopaminergic neurons develop PD pathologic changes: a second case report.Movement disorders : official journal of the Movement Disorder Society. 23(16) : 2303-6, 2008.
Olanow CW, Hauser RA, Jankovic J, Langston W, Lang A, Poewe W, Tolosa E, Stocchi F, Melamed E, Eyal E, Rascol O. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson''s disease (the ADAGIO study): rationale, design, and baseline characteristics.Movement disorders : official journal of the Movement Disorder Society. 23(15) : 2194-201, 2008.
Hauser RA, Shulman LM, Trugman JM, Roberts JW, Mori A, Ballerini R, Sussman NM. Study of istradefylline in patients with Parkinson''s disease on levodopa with motor fluctuations.Movement disorders : official journal of the Movement Disorder Society. 23(15) : 2177-85, 2008.
Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson''s disease.Nature medicine. 14(5) : 504-6, 2008.
Zesiewicz TA, Shimberg WR, Hauser RA, Robinson W, Wilson MC, Sullivan KL. Chorea as a side effect of gabapentin (Neurontin) in a patient with complex regional pain syndrome Type 1.Clinical rheumatology. 27(3) : 389-90, 2008.
Goetz CG, Wuu J, McDermott MP, Adler CH, Fahn S, Freed CR, Hauser RA, Olanow WC, Shoulson I, Tandon PK, Leurgans S. Placebo response in Parkinson''s disease: comparisons among 11 trials covering medical and surgical interventions.Movement disorders : official journal of the Movement Disorder Society. 23(5) : 690-9, 2008.
Olanow, C. Warren|Hauser, Robert A.|Jankovic, Joseph|Langston, William|Lang, Anthony|Poewe, Werner|Tolosa, Eduardo|Stocchi, Fabrizio|Melamed, Eldad|Eyal, Eli|Rascol, Olivier A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristicsMovement Disorders. 23(15) , 2008.
Simon, David K.|Swearingen, Christopher J.|Hauser, Robert A.|Trugman, Joel M.|Aminoff, Michael J.|Singer, Carlos|Truong, Daniel|Tilley, Barbara C. Caffeine and Progression of Parkinson DiseaseClinical Neuropharmacology. 31(4) , 2008.
Simon DK, Swearingen CJ, Hauser RA, Trugman JM, Aminoff MJ, Singer C, Truong D, Tilley BC. Caffeine and progression of Parkinson disease.Clinical neuropharmacology. 31(4) : 189-96, 2008.
Zesiewicz, Theresa A.|Shimberg, W. Reed|Hauser, Robert A.|Robinson, Wendy|Wilson, Maria-Carmen|Sullivan, Kelly L. Chorea as a side effect of gabapentin (Neurontin®) in a patient with complex regional pain syndrome Type 1Clinical Rheumatology [07703198]. 27(3) , 2008.
Zesiewicz, Theresa A.|Sullivan, Kelly L.|Hoffmann, Michael|Benes, Lourdes M.|Smith, Donald A.|Ward, Christopher L.|Hauser, Robert A. Delayed Thalamic Intracranial Hemorrhage in an Essential Tremor Patient following Deep Brain StimulationEuropean Neurology [00143022]. 59(3-4) , 2008.
Zesiewicz TA, Sullivan KL, Hoffmann M, Benes LM, Smith DA, Ward CL, Hauser RA. Delayed thalamic intracranial hemorrhage in an essential tremor patient following deep brain stimulation.European neurology. 59(3-4) : 187-9, 2008.
Shimberg, W. Reed|Patel, Neha B.|Sullivan, Kelly L.|Hauser, Robert A.|Zesiewicz, Theresa A. Levetiracetam for Stiff-Person Syndrome: Report of 2 PatientsClinical Neuropharmacology [03625664]. 31(5) , 2008.
Hauser, Robert A. Levodopa: Past, Present, and FutureEuropean Neurology. 62(1) , 2008.
Encarnacion, Elmyra V.|Hauser, Robert A. Levodopa-Induced Dyskinesias in Parkinson’s Disease: Etiology, Impact on Quality of Life, and TreatmentsEuropean Neurology. 60(2) , 2008.
Encarnacion EV, Hauser RA. Levodopa-induced dyskinesias in Parkinson''s disease: etiology, impact on quality of life, and treatments.European neurology. 60(2) : 57-66, 2008.
Kordower, Jeffrey H|Chu, Yaping|Hauser, Robert A|Freeman, Thomas B|Olanow, C Warren Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's diseaseNature Medicine. 14(5) , 2008.
Freeman, Thomas B.|Chu, Yaping|Hauser, Robert|Olanow, Warren|Kordower, Jeffrey H. Parkinson's Disease Pathology in Nigral Grafts 14 Years after Transplantation: 865Neurosurgery [0148396X]. 62(6) , 2008.
Goetz, Christopher G.|Wuu, Joanne|McDermott, Michael P.|Adler, Charles H.|Fahn, Stanley|Freed, Curt R.|Hauser, Robert A.|Olanow, Warren C.|Shoulson, Ira|Tandon, P.K.|Leurgans, Sue Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventionsMovement Disorders. 23(5) , 2008.
Hauser, Robert A.|Shulman, Lisa M.|Trugman, Joel M.|Roberts, John W.|Mori, Akihisa|Ballerini, Rocco|Sussman, Neil M. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuationsMovement Disorders. 23(15) , 2008.
Kordower, Jeffrey H.|Chu, Yaping|Hauser, Robert A.|Olanow, C.Warren|Freeman, Thomas B. Transplanted dopaminergic neurons develop PD pathologic changes: A second case reportMovement Disorders. 23(16) , 2008.
Seeberger LC, Hauser RA. Optimizing bioavailability in the treatment of Parkinson''s disease.Neuropharmacology. 53(7) : 791-800, 2007.
Sullivan KL, Ward CL, Hauser RA, Zesiewicz TA. Prevalence and treatment of non-motor symptoms in Parkinson''s disease.Parkinsonism & related disorders. 13(8) : 545, 2007.
Zesiewicz TA, Patel-Larson A, Hauser RA, Sullivan KL. Social Security Disability Insurance (SSDI) in Parkinson''s disease.Disability and rehabilitation. 29(24) : 1934-6, 2007.
Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, De Deyn PP, Lang AE. Ten-year follow-up of Parkinson''s disease patients randomized to initial therapy with ropinirole or levodopa.Movement disorders : official journal of the Movement Disorder Society. 22(16) : 2409-17, 2007.
Simonson W, Hauser RA, Schapira AH. Role of the pharmacist in the effective management of wearing-off in Parkinson''s disease.The Annals of pharmacotherapy. 41(11) : 1842-9, 2007.
Zesiewicz TA, Sullivan KL, Ward CL, Hauser RA. Tiagabine and exacerbation of essential tremor.Movement disorders : official journal of the Movement Disorder Society. 22(14) : 2132-3, 2007.
Zesiewicz TA, Ward CL, Hauser RA, Salemi JL, Siraj S, Wilson MC, Sullivan KL. A pilot, double-blind, placebo-controlled trial of pregabalin (Lyrica) in the treatment of essential tremor.Movement disorders : official journal of the Movement Disorder Society. 22(11) : 1660-3, 2007.
Zesiewicz TA, Sullivan KL, Hauser RA. Levodopa-induced dyskinesia in Parkinson''s disease: epidemiology, etiology, and treatment.Current neurology and neuroscience reports. 7(4) : 302-10, 2007.
Hauser RA, Zesiewicz TA. Advances in the pharmacologic management of early Parkinson disease.The neurologist. 13(3) : 126-32, 2007.
Samanta J, Hauser RA. Duodenal levodopa infusion for the treatment of Parkinson''s disease.Expert opinion on pharmacotherapy. 8(5) : 657-64, 2007.
Hauser RA, Salin L, Juhel N, Konyago VL. Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson''s disease.Movement disorders : official journal of the Movement Disorder Society. 22(3) : 359-65, 2007.
Zesiewicz TA, Ward CL, Hauser RA, Sanchez-Ramos J, Staffetti JF, Sullivan KL. A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.Movement disorders : official journal of the Movement Disorder Society. 22(2) : 279-82, 2007.
Zesiewicz TA, Ward CL, Hauser RA, Pease Campbell JA, Sullivan KL. Pregabalin (Lyrica) in the treatment of essential tremor.Movement disorders : official journal of the Movement Disorder Society. 22(1) : 139-41, 2007.
Zesiewicz, Theresa A.|Ward, Christopher L.|Hauser, Robert A.|Sanchez‐Ramos, Juan|Staffetti, Joseph F.|Sullivan, Kelly L. A double‐blind placebo‐controlled trial of zonisamide (zonegran) in the treatment of essential tremorMovement Disorders. 22(2) , 2007.
Zesiewicz, Theresa A.|Ward, Christopher L.|Hauser, Robert A.|Salemi, Jason L.|Siraj, Shaila|Wilson, Maria‐Carmen|Sullivan, Kelly L. A pilot, double‐blind, placebo‐controlled trial of pregabalin (Lyrica) in the treatment of essential tremorMovement Disorders. 22(11) , 2007.
Hauser, Robert A.|Zesiewicz, Theresa A. Advances in the Pharmacologic Management of Early Parkinson DiseaseNeurologist. 13(3) , 2007.
Stacy, M.|Hauser, R. Development of a Patient Questionnaire to facilitate recognition of motor and non-motor wearing-off in Parkinson’s diseaseJournal of Neural Transmission [03009564]. 114(2) , 2007.
Samanta, Johan|Hauser, Robert A Duodenal levodopa infusion for the treatment of Parkinson’s diseaseExpert Opinion on Pharmacotherapy. 8(5) , 2007.
Taylor, Julie P.|Hulihan, Mary M.|Kachergus, Jennifer M.|Melrose, Heather L.|Lincoln, Sarah J.|Hinkle, Kelly M.|Stone, Jeremy T.|Ross, Owen A.|Hauser, Robert|Aasly, Jan|Gasser, Thomas|Payami, Haydeh|Wszolek, Zbigniew K.|Farrer, Matthew J. Leucine-rich repeat kinase 1: a paralog of LRRK2 and a candidate gene for Parkinson’s diseaseNeurogenetics. 8(2) , 2007.
Zesiewicz, Theresa A.|Sullivan, Kelly L.|Hauser, Robert A. Levodopa-induced Dyskinesia in Parkinson’s disease: Epidemiology, etiology, and treatmentCurrent Neurology and Neuroscience Reports. 7(4) , 2007.
Zesiewicz, Theresa A.|Hauser, Robert A. MEDICAL TREATMENT OF MOTOR AND NONMOTOR FEATURES OF PARKINSON'S DISEASECONTINUUM: Lifelong Learning in Neurology [10802371]. 13, 2007.
Seeberger, Lauren C.|Hauser, Robert A. Optimizing bioavailability in the treatment of Parkinson's diseaseNeuropharmacology [00283908]. 53(7) , 2007.
Langbehn, Douglas R.|Paulsen, Jane S. Predictors of diagnosis in Huntington diseaseNeurology. 68(20) , 2007.
Zesiewicz, Theresa A.|Ward, Christopher L.|Hauser, Robert A.|Pease Campbell, Jessica A.|Sullivan, Kelly L. Pregabalin (Lyrica) in the treatment of essential tremorMovement Disorders. 22(1) , 2007.
Sullivan, Kelly L.|Ward, Christopher L.|Hauser, Robert A.|Zesiewicz, Theresa A. Prevalence and treatment of non-motor symptoms in Parkinson's diseaseParkinsonism and Related Disorders. 13(8) , 2007.
Hauser, Robert A.|Salin, Laurence|Juhel, Nolwenn|Konyago, Victor L. Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's diseaseMovement Disorders. 22(3) , 2007.
Simonson, W.|Hauser, R. A|Schapira, A. H. Role of the Pharmacist in the Effective Management of Wearing-Off in Parkinson's DiseaseThe Annals of Pharmacotherapy. 41(11) , 2007.
Zesiewicz, T. A.|Patel-Larson, A.|Hauser, R. A.|Sullivan, K. L. Social Security Disability Insurance (SSDI) in Parkinson's diseaseDisability and Rehabilitation [09638288]. 29(24) , 2007.
Hauser, Robert A.|Rascol, Olivier|Korczyn, Amos D.|Jon Stoessl, A.|Watts, Ray L.|Poewe, Werner|De Deyn, Peter P.|Lang, Anthony E. Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopaMovement Disorders. 22(16) , 2007.
Zesiewicz, Theresa A.|Sullivan, Kelly L.|Ward, Christopher L.|Hauser, Robert A. Tiagabine and exacerbation of essential tremorMovement Disorders [08853185]. 22(14) , 2007.
Zesiewicz, Theresa A.|Sullivan, Kelly L.|Hauser, Robert A. Chorea Induced by LamotrigineJournal of Child Neurology [08830738]. 21(4) , 2006.
Hauser, Robert A.|Zesiewicz, Theresa A. Clinical trials aimed at detecting neuroprotection in Parkinson’s diseaseNeurology [00283878]. 66(10_suppl_4) , 2006.
Graff-Radford, John|Foote, Kelly D.|Rodriguez, Ramon L.|Fernandez, Hubert H.|Hauser, Robert A.|Sudhyadhom, Atchar|Rosado, Christian A.|Sanchez, Justin C.|Okun, Michael S. Deep Brain Stimulation of the Internal Segment of the Globus Pallidus in Delayed Runaway DyskinesiaArchives of Neurology. 63(8) , 2006.
Stacy, Mark|Hauser, Robert|Oertel, Wolfgang|Schapira, Anthony|Sethi, Kapil|Stocchi, Fabrizio|Tolosa, Eduardo End-of-dose Wearing Off in Parkinson Disease: A 9-Question Survey AssessmentClinical Neuropharmacology. 29(6) , 2006.
Hauser, Robert A. Factors Associated With the Development of Motor Fluctuations and Dyskinesias in Parkinson DiseaseArchives of Neurology. 63(12) , 2006.
Samanta, Johan|Hauser, Robert A Levodopa/carbidopa/entacapone for the treatment of Parkinson's diseaseAging Health. 2(2) , 2006.
Pahwa, Rajesh|Lyons, Kelly E.|Wilkinson, Steven B.|Simpson, Richard K.|Ondo, William G.|Tarsy, Daniel|Norregaard, Thorkild|Hubble, Jean P.|Smith, Donald A.|Hauser, Robert A.|Jankovic, Joseph Long-term evaluation of deep brain stimulation of the thalamusJournal of Neurosurgery Pediatrics [00223085]. 104(4) , 2006.
Zesiewicz, Theresa A|Sullivan, Kelly L|Hauser, Robert A Nonmotor symptoms of Parkinson’s diseaseExpert Review of Neurotherapeutics. 6(12) , 2006.
Zesiewicz, Theresa A.|Sullivan, Kelly L.|Hauser, Robert A.|Sanchez‐Ramos, Juan Open‐label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's diseaseMovement Disorders. 21(11) , 2006.
Hauser, Robert A.|Russ, Hermann|Haeger, Doris-Anita|Bruguiere-Fontenille, Michel|Müller, Thomas|Wenning, Gregor K. Patient Evaluation of a Home Diary to Assess Duration and Severity of Dyskinesia in Parkinson DiseaseClinical Neuropharmacology. 29(6) , 2006.
Sullivan, Kelly L.|Staffetti, Joseph F.|Hauser, Robert A.|Dunne, Peter B.|Zesiewicz, Theresa A. Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's diseaseMovement Disorders. 21(1) , 2006.
Zesiewicz, Theresa A.|Wecker, Lynn|Sullivan, Kelly L.|Merlin, Lisa R.|Hauser, Robert A. The Controversy Concerning Plasma Homocysteine in Parkinson Disease Patients Treated with Levodopa Alone or with Entacapone: Effects of Vitamin StatusClinical Neuropharmacology. 29(3) , 2006.
Zesiewicz, Theresa A.|Tullidge, Archer|Tidwell, Jonathan|Sullivan, Kelly L.|Hauser, Robert A. Topiramate-induced Psychosis in Patients with Essential Tremor: Report of 2 CasesClinical Neuropharmacology [03625664]. 29(3) , 2006.
Zesiewicz, Theresa A.|Pathak, Amit|Sullivan, Kelly L.|Shamayev, Mikhail|Hauser, Robert A. Treatment of chorea with levetiracetamEuropean Journal of Clinical Pharmacology. 62(1) , 2006.
Wolfrath, Summer C.|Borenstein, Amy R.|Schwartz, Skai|Hauser, Robert A.|Sullivan, Kelly L.|Zesiewicz, Theresa A. Use of nutritional supplements in Parkinson's disease patientsMovement Disorders. 21(8) , 2006.
Zesiewicz, Theresa A.|Sullivan, Kelly L.|Hauser, Robert A. Vascular hemichorea/hemiballismus and topiramateMovement Disorders. 21(4) , 2006.
Hauser, Robert A|Schwarzschild, Michael A Adenosine A2A Receptor Antagonists for Parkinson???s Disease: Rationale, Therapeutic Potential and Clinical ExperienceDrugs and Aging. 22(6) , 2005.
Recio, Maria V.|Hauser, Robert A.|Louis, Elan D.|Radhashakar, Harsha|Sullivan, Kelly L.|Zesiewicz, Theresa A. Chorea in a patient with cerebral palsy: Treatment with levetiracetamMovement Disorders. 20(6) , 2005.
Truong, Daniel|Duane, Drake D.|Jankovic, Joseph|Singer, Carlos|Seeberger, Lauren C.|Comella, Cynthia L.|Lew, Mark F.|Rodnitzky, Robert L.|Danisi, Fabio O.|Sutton, James P.|Charles, P. David|Hauser, Robert A.|Sheean, Geoffrey L. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: Results of the first US randomized, double‐blind, placebo‐controlled studyMovement Disorders. 20(7) , 2005.
Stacy, Mark|Bowron, Annette|Guttman, Mark|Hauser, Robert|Hughes, Kim|Larsen, Jan Petter|LeWitt, Peter|Oertel, Wolfgang|Quinn, Niall|Sethi, Kapil|Stocchi, Fabrizio Identification of motor and nonmotor wearing‐off in Parkinson's disease: Comparison of a patient questionnaire versus a clinician assessmentMovement Disorders. 20(6) , 2005.
Hogarth, Penelope|Kayson, Elise|Kieburtz, Karl|Marder, Karen|Oakes, David|Rosas, Diana|Shoulson, Ira|Wexler, Nancy S.|Young, Anne B.|Zhao, Hongwei Interrater agreement in the assessment of motor manifestations of Huntington's diseaseMovement Disorders. 20(3) , 2005.
Sullivan, Kelly L.|Hauser, Robert A.|Zesiewicz, Theresa A. Levetiracetam for the treatment of essential tremorMovement Disorders. 20(5) , 2005.
Sullivan, Kelly L.|Hauser, Robert A.|Louis, Elan D.|Chari, Ganesh|Zesiewicz, Theresa A. Levetiracetam for the treatment of generalized dystoniaParkinsonism and Related Disorders. 11(7) , 2005.
Zesiewicz, Theresa A|Sanchez-Ramos, Juan|Sullivan, Kelly L|Hauser, Robert A Levetiracetam-Induced Parkinsonism in a Huntington Disease PatientClinical Neuropharmacology. 28(4) , 2005.
Zesiewicz, Theresa A.|Sullivan, Kelly L.|Maldonado, John L.|Tatum, William O.|Hauser, Robert A. Open‐label pilot study of levetiracetam (Keppra) for the treatment of levodopa‐induced dyskinesias in Parkinson's diseaseMovement Disorders. 20(9) , 2005.
Furtado, Sarah|Sossi, Vesna|Hauser, Roberta A.|Samii, Ali|Schulzer, Michael|Murphy, Colleen B.|Freeman, Thomas B.|Stoessl, A. Jon Positron emission tomography after fetal transplantation in Huntington's diseaseAnnals of Neurology. 58(2) , 2005.
Zesiewicz, T. A.|Elble, R.|Louis, E. D.|Hauser, R. A.|Sullivan, K. L.|Dewey, R. B.|Ondo, W. G.|Gronseth, G. S.|Weiner, W. J. Practice Parameter: Therapies for essential tremor [RETIRED]: Report of the Quality Standards Subcommittee of the American Academy of NeurologyNeurology. 64(12) , 2005.
Zesiewicz, Theresa A|Stamey, William|Sullivan, Kelly L|Hauser, Robert A Botulinum toxin A for the treatment of cervical dystoniaExpert Opinion on Pharmacotherapy. 5(9) , 2004.
Hauser, Robert A.|Pahwa, Rajesh Current treatment challenges and emerging therapies in Parkinson's diseaseNeurologic Clinics. 22(3) , 2004.
Stern, Matthew B.|Marek, Kenneth L.|Friedman, Joseph|Hauser, Robert A.|LeWitt, Peter A.|Tarsy, Daniel|Olanow, C. Warren Double‐blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patientsMovement Disorders. 19(8) , 2004.
Sullivan, Kelly L.|Hauser, Robert A.|Zesiewicz, Theresa A. Essential Tremor: Epidemiology, Diagnosis, and TreatmentNeurologist. 10(5) , 2004.
Hauser, Robert A.|Lyons, Kelly E. Future therapies for Parkinson's diseaseNeurologic Clinics. 22(3) , 2004.
Zesiewicz, T.A.|Strom, J.A.|Borenstein, A.R.|Hauser, R.A.|Cimino, C.R.|Fontanet, H.L.|Cintron, G.B.|Staffetti, J.F.|Dunne, P.B.|Sullivan, K.L. Heart failure in Parkinson's disease: analysis of the United States medicare current beneficiary surveyParkinsonism and Related Disorders. 10(7) , 2004.
Hauser, Robert A. Levodopa/carbidopa/entacapone (Stalevo)Neurology [00283878]. 62(1_suppl_1) , 2004.
Hauser, Robert A.|Deckers, Frieda|Lehert, Philippe Parkinson's disease home diary: Further validation and implications for clinical trialsMovement Disorders. 19(12) , 2004.
Adler, C. H.|Hauser, R. A.|Sethi, K.|Caviness, J. N.|Marlor, L.|Anderson, W. M.|Hentz, J. G. Ropinirole for restless legs syndrome: A placebo-controlled crossover trialNeurology [00283878]. 62(8) , 2004.
Pahwa, Rajesh|Lyons, Kelly E|Hauser, Robert A Ropinirole therapy for Parkinson’s diseaseExpert Review of Neurotherapeutics. 4(4) , 2004.
Zesiewicz, Theresa A.|Louis, Elan D.|Sullivan, Kelly L.|Menkin, Martin|Dunne, Peter B.|Hauser, Robert A. Substantial improvement in a Meige's syndrome patient with levetiracetam treatmentMovement Disorders. 19(12) , 2004.
Waters, Cheryl H.|Sethi, Kapil D.|Hauser, Robert A.|Molho, Eric|Bertoni, John M. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3‐month, randomized, placebo‐controlled studyMovement Disorders. 19(4) , 2004.
Kordower, Jeffrey H.|Freeman, Thomas B.|Chen, Er‐Yun|Mufson, Elliott J.|Sanberg, Paul R.|Hauser, Robert A.|Snow, Barry|Warren Olanow, C. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's diseaseMovement Disorders. 13(3) , 1998.